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Protein Engineering Strategy for the Stabilization of HIV-1 α-Helical Peptides 
Many disease-relevant protein-protein interactions (PPIs) contain an alpha helix and 
helical binding cleft at their interface. Disruption of these interactions with helical peptide 
mimics is a validated therapeutic strategy. However, short peptides typically do not fold into 
stable helices, which significantly lowers their in vivo stability. Researches have reported 
methods for helical peptide stabilization but, these approaches rely on laborious, and often 
expensive, chemical synthesis and purification. The research I have preformed aims to stabilize 
disease-relevant helices through protein engineering. In contrast to chemically constrained 
helical peptides, a protein can be expressed in a cellular system on a much larger scale. Recently, 
we reported a new strategy termed “helix-grafted display” that overcomes the traditional hurdles 
of helical mimics and applied it to the challenge of suppressing HIV entry. Our helix grafted 
proteins, potently inhibits formation of the extracellular PPI involving C-peptide helix, and HIV 
gp41 N-peptide trimer, as tested in HIV CD4+ cells. Further optimization of the helical sequence 
by yeast display yielded new proteins that suppress HIV-1 entry and express substantially better 
in E. coli. Furthermore, fusion proteins designed to improve the serum stability of these helix 
grafted proteins have been made that potently suppress HIV-1 entry. Collectively, I report a 
potential cocktail of evolved HIV-1 entry inhibitors that are functional against an Enfuvirtide-
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1.1 Impacts of Human Immunodeficiency Virus and Acquired Immune Deficiency 
Syndrome 
Human Immunodeficiency Virus (HIV) is considered one of the most dangerous viruses 
known to mankind. HIV is able to infect a host’s healthy immune cell, integrate its viral DNA 
into the human genome, and hijack the cells machinery to produce more virions.1 While the 
mechanism is not entirely understood, the once healthy (immune) T-cells die and a person’s 
immune system slowly deteriorates. When the T-cell count reaches below 200 (normal T-cell 
count is 500-1500) patients are diagnosed with Acquired Immune Deficiency Syndrome 
(AIDS).2 HIV/AIDS has killed approximately 35 million due to AIDS related illnesses and there 
are currently 37 million people living with HIV/AIDS as of 2017.3, 4 Reports project there will be 
2 million newly infected HIV+ patients every year and an estimated one million will die 
worldwide despite having medications that can prevent HIV infection and therapeutics that can 
slow down the progression of AIDS.1  
It is believed that HIV first emerged in West Africa during the 1930s, most likely during a 
hunting expedition when a man came into contact with blood from a chimpanzee.5 The first five 
reported cases of HIV in the United States were reported on June 5 1981.6 By 1990 an estimated 
10 million people were living with HIV worldwide. This number jumped to 30 million in just 
seven years and by 1999, 14 million people died due to AIDS related illnesses since the start of 
the viral outbreak. 
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With such a high mortality rate in a short matter of time, HIV+ patients and the world began 
searching for therapeutics to treat the virus and prevent infection. Six years after the initial 
reported cases of AIDS in the United States, the FDA approved its first small molecule HIV 
drug. However, HIV has been able to evade therapeutic intervention due to its adaptability. The 
virus is able to replicate 100,000 billion times per day, which allows it to continuously attack 
healthy cells. The virus also has a reverse transcriptase (discussed further below) that is highly 
prone to inserting mutations in the viral genome, allowing the virus to evolve quickly. HIV’s 
high replication rate and ability to mutate and evolve resulted in a drug resistance problem. In 
1996 it was discovered that patients needed to be enrolled in antiretroviral therapy.7 
Antiretroviral therapy, also known as ART, is a combination therapy of at least two drugs that 
target different parts of viral infection. Patients who are prescribed ART must follow the strict 
regime of drugs for the rest of their lives to combat the virus’ ability to mutate and evolve. 
Combination therapy put a large demand on the number of available drugs targeting HIV. In 
some cases, patients were taking an astounding 6 pills a day and paying $10,000 per year, but 
those patients were able to combat the progression of AIDS. Despite having 28 FDA approved 
drugs in 2018, many patients throughout the world cannot gain access to these treatments 
because of their enormous cost.  
1.2 HIV-1 Viral Life Cycle 
To build a large repertoire of drugs targeting HIV, researchers needed to understand how the 
virus works to tailor drugs to interrupt specific protein interactions. HIV is a retrovirus meaning 
it’s a type of RNA virus.8 HIV first enters the bloodstream and binds to a CD4+ cell (healthy 
immune/T-cell, Step 1). The viral membrane then undergoes conformational rearrangements 
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with the host cell allowing for the virus to inject its genetic material (Step 2). This genetic 
material includes its single stranded RNA (ssRNA), and its enzymes including reverse 
transcriptase, integrase and protease. The ssRNA is then transcribed into double stranded DNA 
by HIV’s reverse transcriptase enzyme (Step 3). The DNA is then shuttled into the host cells 
nucleus along with integrase. The host cells DNA is then cut and HIV’s double stranded DNA is 
inserted, or integrated into the genome (Step 4). From there the virus is able to use the host cells 
machinery to turn on transcription and translation to produce long chains of viral protein (Step 
5). This long protein chain is then transported towards the surface of the cell. These proteins then 
assemble into an immature virion (Step 6). The immature HIV particle begins to bud off (Step 7) 
and the long protein chain is cut by HIV’s protease to produce smaller functional proteins to 
make a mature virion (Step 8). These virions can then move on to attack a new CD4+ cell.9  
cytosol
CD4

















Figure 1.1 Schematic of HIV viral life cycle. The virus recognizes CD4+ immune cell, injects its RNA and 
viral proteins. The virus is able to hijack the hosts cells machinery to integrate its viral DNA and produce 
more virions. 
	 4	
1.3 Current Treatments for HIV-1 
There are currently 28 individual drugs on the market targeting HIV and most are taken in 
combination as an antiretroviral therapy. The drugs are classified under 4 categories based on 
their targets: viral entry, reverse transcriptase (non-nucleoside and nucleoside), integrase or 
protease. Most of the current drugs on the market are small molecule inhibitors targeting HIV’s 
reverse transcriptase or protease. Surprisingly, of the 28 approved drugs only three of them target 
viral entry, and two of them are biologics (peptide or antibody drugs). Viral entry inhibitors are 
able to block initial receptor binding, co-receptor activation or membrane fusion. While these 
viral entry inhibitors are effective, they are considered a last resort treatment because they are 
costly to make, require multiple injections and/or have severe side effects. Due to its rapid 
replication cycle, there is a strong need for improved entry inhibitors that can be produced on a 
large scale and remain in the blood stream. The focus of this thesis pertains to investigating a 
protein engineering solution to inhibit fusion of the HIV viral particle to healthy immune cells. 
This therapeutic needs to be produced on a large scale, display good in vivo stability, be readily 
evolvable and be a potent membrane fusion inhibitor 
 
1.4 Membrane Fusion and Entry Inhibitors 
HIV uses its glycoproteins to recognize CD4 receptors on the outside of T-cells. Gp120 is 
what recognizes and binds CD4 on the host cell. Gp120 then sheds itself allowing gp41 to insert 
a N-terminal fusion peptide into the target cells bilayer, forming a bridge between the virus 
membrane and target cell membrane, known as the pre-hairpin intermediate. The pre-hairpin 
intermediate consists of a trimer of hairpins that expose both N and C peptides. After the virus 
anchors itself to the immune cell it folds over and brings the two membranes closer together 
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forming a six helical bundle. This bundle formation allows the virus to inject its genetic material 
ultimately leading to infection.  
α-Helical peptides derived from the N-peptide trimer or C-peptide trimer of gp41 are a 
validated therapeutic approach for targeting membrane fusion. These peptides are able to bind to 
the exposed groves in the pre-hairpin intermediate and impede six helical bundle formation. 
NHR peptides are able to inhibit infection with micromolar concentrations but often aggregate 
because of their hydrophobic residues.10 C-peptides have proven to be more potent and effective 
than NHR peptides and can effectively inhibit HIV-1 viral membrane fusion in nanomolar 
concentrations.11 A crystal structure of the full length N- (tan) and C- peptide (navy) hairpin 
interaction is shown below (Figure 1.3A). Enfuvirtide (also known as T-20 or Fuzeon), is 
currently the only FDA approved peptide therapeutic for HIV that specifically blocks viral 
membrane fusion by binding the N peptide trimers and obstructing 6 helix bundle formation. Its 
36 amino acid sequence directly comes from gp41. Making a peptide drug of such a long 























Figure 1.2 HIV-1 membrane fusion is enabled by HIV’s glycoproteins. GP120 recognizes the CD4 
receptor on immune cells. Gp120 undergoes a confirmation rearrangement exposing gp41. GP41 is 
able to anchor itself into the host cell’s membrane leading to a ‘trimer-of-hairpins’ assembly involving 
N-peptide and C-peptide trimers. This leads to juxtaposition of viral and immune cell membranes, and 
viral entry. 
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1.5 Drawbacks of α-Helical Peptides 
Despite their success, α-helical peptides still have considerable drawbacks, namely cost of 
production and sensitivity to degradation. Enfuvirtide is a classic example of these setbacks and 
is considered to be a last resort treatment for HIV patients. Enfuvitide has a half of ~3.4 hours 
which requires patients to undergo twice daily injections which is less than ideal for them. 
Proteolytic stability is a common issue for α-helical peptides because they are often found 
disordered in solution, which makes them susceptible to degradation. In order for a peptide to 
bind its desired target a large entropic cost is required for it go from its partially unfolded state to 
an ordered conformation.12 Peptide therapeutics have sought to overcome the limitations of 
helical peptides by methods of stabilization and structured mimics.13 Helix stabilization 
constrains the peptide so it can no longer move freely. Common methods for this are forming salt 
bridges, chelation with metals, hydrocarbon stapling and covalent cyclization.13 Helical mimics 
imitate the topography of the peptide, allowing for correct orientations of the functional groups. 
Approaches for this includes using α/β peptides, terphenyls, and peptoids.14 These methods have 
shortcomings of their own and can result in a decrease of the original peptide’s potency.15 
Increased optimization is still of significant interest despite the development of new strategies for 














































Figure 1.3 (A) GP41 derived membrane fusion inhibitors. (B) Amino acid sequence of Enfuvirtide 
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1.6 Protein Engineering Solution to Helix Stabilization 
Protein grafting could be an ideal method for helix stabilization due to its large success with 
N- and C-peptides as HIV-1 gp41-1 binders. Protein grafting is used to	 transfer the biological
function of a ligand onto the surface of another protein.16 Kim and co-workers applied this 
method with the C-peptide of HIV-1, grafting it onto a GCN4 leucine zipper.15 Their protein, 
C34-GCN4, showed similar activity to the native C-peptide. However, helix stabilization is still a 
challenge when grafting onto a pre-established helical interface and still required expensive 
peptide synthesis. We hypothesized a protein with a solvent exposed helix could be stabilized by 
its tertiary structure and would be better suited for grafting since it can be expressed in E coli.  
Pleckstrin Homology (PH) domains have a C-terminal solvent exposed helix that fits in a 
cleft formed by the surrounding β-sheets.17 These domains are generally found in proteins 
involved in cell trafficking and function in binding phosphoinositides.13 These proteins are ~120 
residues which makes for quick insertion into a bacterial vector. The native function of PH 
domains can also be turned off by a single mutation via site directed mutagenesis. The 











Figure 1.4 Proposed protein engineering strategy for creating stable HIV membrane fusion inhibitors. 
Solvent exposed residue on a PH domain we will be mutated to match residues from a HIV-1 disease 
relevant peptide. The resulting helix-grafted protein will be expressed in E. coli and tested for function. 
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tertiary structure. If those residues were untouched and only solvent exposed helical residues 
mutated, the interface could be altered to match the binding face of the peptide. Figure 1.4 
depicts the helix grafted display method developed in the McNaughton/Kennan laboratories 
1.7 Scope of This Thesis 
This thesis will describe a protein engineering solution to stabilizing an HIV relevant peptide, 
termed C-peptide. By using PH domains as a generic scaffold we were able to mutate and extend 
their helix to mimic that of C-peptide. These proteins could be produced in E. coli and remained 
folded in solution, overcoming proteolytic stability issues and laborious chemical synthesis 
associated with α-helical peptides. These proteins tightly bind a model of membrane fusion and 
are also potent fusion inhibitors in a live virus assay. We also found that the solvent exposed 
helix was amenable to mutations and could be optimized for higher binding affinity to a 
membrane fusion model. By diversifying the helix we found numerous fusion inhibitors that 
could potentially be used as a cocktail therapy. Our helix-grafted proteins can also be fused to 
antibody mimics for stability, giving these proteins the potential to remain in the bloodstream for 
long periods of time and still inhibit HIV viral infection.  
Chapter II details our initial helix grafted display efforts on a scaffold called GLUE. GLUE, 
(GRAM-Like Ubiquitin-binding in EAP45) is a PH domain endogenous to yeast, which can be 
easily expressed in E. coli with a His6 tag. We found that GLUE’s native helix can be mutated to 
match that of HIV’s gp41 C-peptide. We termed this engineered protein GLUE Cpep. GLUE 
Cpep is folded in solution, stable in human serum, and soluble in aqueous solutions and thus 
overcomes challenges faced by peptides derived from HIV gp41. 18 
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Chapter III is an expansion of our proof concept model, GLUE-Cpep. To develop the helix 
grafted display platform we prepared a number of human-derived helix grafted PH domains of 
varied helix length and measured properties relevant to therapeutic and basic research 
applications. In particular we showed that some of these new reagents expressed well as 
recombinant proteins, were relatively stable in human serum, bound a mimic of pre-fusogenic 
HIV-1 gp41 in vitro and in complex biological environments, and significantly lowered the 
incidence of HIV-1 infection of CD4-positive cells. 19 
In Chapter IV we take Cpep ELMO, a helix grafted protein found in Chapter III and used 
yeast display to screen a library of grafted C-peptide helices for N-peptide trimer recognition. 
Using hits from the yeast display library screening, we evaluated the effect the helix mutations 
have on structure, expression, stability function and suppression of HIV entry in a live virus 
assay.20 
Chapter IV describes our most potent entry inhibitor yet, Sac7d-Cpep. Our previous scaffolds 
in Chapter III and IV inhibited membrane fusion in a live virus assay, albeit, modestly (IC50 190 
nM - >1 µM). Sac7d Cpep on the other hand is able to suppress HIV-1 infection with an IC50 of 
1.9-12.4 nM. This is competitive with Enfuvirtide and C-peptide, whose IC50s are 0.7-3.5 nM 
and 1.0-6.7 nM, respectively. Yeast display sequence optimization of solvent exposed helix 
residues, similar to the work done in Chapter IV, revealed new proteins with improved 
expression in E. coli, and no appreciable change in entry inhibition. Evolved proteins inhibit the 
entry of a clinically relevant mutant of HIV-1 that is gp41 C-peptide sensitive and Enfuvirtide-
resistant. Fusion proteins were then designed for serum stability and also potently suppress HIV-
1 entry. 21
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This thesis describes four different stories entailing the development and evolution of 
stable HIV-1 gp41 C-peptide membrane fusion inhibitors. We found that the starting PH domain 
or PH-like domain scaffold needs to be robustly expressed in E. coli and amenable to mutation. 
Since viral membrane fusion is an enclosed space the inhibitors potency is size dependent. Some 
of our newly found helix grafted proteins are able to inhibit HIV infection in Enfuvirtide resitant 
strains, which goes to show the adaptability and utility of our helix-grafted display platform. 
These new biologics can be fused to antibody-derived proteins for improved in vivo stability. 
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CHAPTER TWO 
GLUE That Sticks to HIV: A Helix-Grafted GLUE Protein That Potently and 




In this work, led by fellow graduate student Susanne Walker, I assisted in molecular 
cloning, protein purification and ELISA experiments. I also performed all circular dichroism 
experiments. 
2.2 Introduction 
A medicinally significant subset of protein-protein interactions consists of those with α-
helix bound to a surface cleft. This has sparked considerable interest in the synthetic replication 
of helical epitopes as a route to novel therapeutics. Various strategies have been employed, 
including oligomeric organic scaffolds that project side chains along appropriate vectors1-3, 
covalently constrained (or ‘stapled’) peptides4-7, and helical ‘foldamers’8-12 employing natural or 
unnatural backbone architectures (as briefly mentioned in Chapter I). Each has produced 
effective agents, but requires non-trivial synthetic effort and expense.  
By exploiting the flexibility and feasibility of protein production in E. coli, its possible a 
more accessible suite of ligands could be generated. In developing a general scaffold for helix 
grafted display, we sought to identify a protein fold that presents a properly folded α-helix within 
the confines of a larger structure, in such a way as to permit direct receptor access to one helical 
1 This work has been adapted from: 
Walker, S. N.;  Tennyson, R. L.;  Chapman, A. M.;  Kennan, A. J.; McNaughton, B. R., GLUE 
that sticks to HIV: a helix-grafted GLUE protein that selectively binds the HIV gp41 N-terminal 
helical region. Chembiochem 2015, 16 (2), 219-22 
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face. Ideally the basic scaffold would be readily expressible in soluble form, tolerant of mutation 
and/or extension of the helix, and protective against rapid helix degradation. The general concept 
of grafting is an established method for mimicking protein surfaces but has only been done by 
grafting one α-helix onto another.13, 14 
Chapter II will describe our successful application of our specific ‘helix-grafting’ 
technique to a PPI crucial for HIV infection. We show that grafting of gp41 C-peptide residues 
onto the exposed helical face of a suitable host affords a new ligand that expresses well in E. 
coli, exhibits excellent serum stability and is capable of replicating the native interaction. 
Peptides derived from this C-peptide helix have been shown to bind the prehairpin intermediate 
and inhibit membrane fusion of HIV in human cells (as described in Chapter I).15-17 We reasoned 
that a helix-grafted alternative might retain similar specificity but have improved stability, 
solubility, and availability. 
2.3 GLUE as a Protein Scaffold for Helix Grafted Display 
In designing our first-generation helix-grafted protein, we focused on a Pleckstrin homology 
(PH) domain called GLUE (GRAM-Like Ubiquitin-binding in EAP45, Figure 2A, gray), which 
is derived from a subunit of the endosomal sorting complex.18 Like other members of the PH 
family, the GLUE domain contains a C-terminal amphipathic helix resting in a cleft formed by 
two opposed beta sheets, with one face presented to solvent. This relatively rare arrangement is 
well suited to serve as a helix-grafting scaffold. Although the native GLUE helix is only 16 
residues, known structures of other PH domains with helices up to 29 residues suggested that it 
16	
could be extended to a length comparable to the C-peptide without structural compromise. In 
addition to its well-positioned helix platform, GLUE is a relatively small (~15 kDa) and stable 
protein. Finally, native GLUE function relies on an affinity for phospholipids that can be 
abolished by a single Arg107Ala mutation, making it suitable for future intracellular targets 
without fear of disrupting lipid trafficking.  
We began by aligning the native helix on GLUE (Figure 2.1A, grey) with a single C-peptide 
helix from gp41 (Figure 2.1A, purple). Backbone atoms from the GLUE helix (PDB code 
2CAY) were aligned with the corresponding number from the N-terminal segment of the gp41 
C-peptide (PDB 1AIK), using PyMol’s pair_fit algorithm. The overlay was very good (RMSD of
0.44 Å over 60 atoms), and it allowed us to confidently select six positions on the GLUE helix at 
which we could install side chains from the gp41 sequence in such a way as to replicate their 
native three-dimensional positions. We then extended the helix by attaching a pure gp41 
sequence to the C-terminus of GLUE (Figure 2.1B) such that the total length of the new helix 
was appropriate for binding to the trimeric N-terminal coiled coil. The final sequence expressed 






Figure 2.1 (A) Helix-grafting HIV gp41 C-peptide onto a stable PH domain protein. Wild-type GLUE 
(grey, bottom) and gp41 C-peptide (purple, top). Sequences of the GLUE helix and the corresponding 
responding region of the gp41 helix are shown in gray and purple, respectively. Spheres indicate the 
C-alpha position (B) Helix-grafted GLUE-Cpep, produced by backbone alignment of the independent
structures. Spheres indicate C-alpha positions of GLUE residues mutated to those from gp41 (also
coded in the sequence).
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2.4 Characterization of GLUE-Cpep 
We characterized both wild-type GLUE (wtGLUE) and the helix-grafted variant (referred 
to as GLUE-Cpep herein) by circular dichroism (CD), to probe for macroscopic structural 
changes (Figure 2.2A). Both proteins display a similar overall signal, suggesting that the 
grafting process does not compromise the GLUE domain fold. Since one element of our design 
was the expectation that a well folded protein domain would exhibit improved serum stability 
compared to an isolated short peptide, we next conducted a serum stability test using a standard 
assay. FLAG-tagged GLUE-Cpep incubated with human serum for up to 12 hours showed no 
appreciable degradation by Western blot analysis (Figure 2.2B). This supports a significant 
serum stability enhancement for the grafted protein compared to isolated peptides such as 
Enfuvirtide. 
2.5 5-Helix Binding Model 
Direct analysis of the binding interaction between GLUE-Cpep and the NHR receptor by 
simple mixing of the two components is complicated by several factors: proper self-assembly of 
A
incubation time (hr) 
0 0.5 1 2 4 8 12 
B
Figure 2.2 (A) Circular Dichroism (CD) data for wtGLUE (black) and GLUE-Cpep (gray). (B) Western blot of 
FLAG-tagged helix grafted GLUE that isn’t incubated with human serum (lane 1), or after 0.5 to 12 hours of 
incubation (lanes 2-7). 
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the N-terminal peptide, the potential for one, two, or three GLUE-derived ligands per complex, 
and the known susceptibility of unbound N-peptide trimers to aggregation/precipitation. 
Fortunately these challenges have long been recognized, and several solutions exist. We chose to 
use a construct called 5-helix, based on initial work by Kim and coworkers. It solves the problem 
of multiple equilibria and binding sites by covalently tethering five of the six subunits with short 
Gly/Ser loops. Thus a single polypeptide contains three copies of the NHR domain and two C-
peptides, such that when folded it features the coiled coil with two of its binding sides already 
occupied, and just a single exposed interface (Figure 2.3A). Throughout, we use 5-helix as a 
receptor to assess complex formation with GLUE-Cpep. Initial CD characterization of the 
GLUE-Cpep/5-helix complex demonstrates binding-induced gains in helicity and thermal 
stability. The wavelength spectrum (Figure 2.3B) exhibits a notably deeper signal for the 1:1 
mixture than for either component alone, and the corresponding melt data (Figure 2.3C) reveal a 
dramatic increase in thermal stability, as evidenced by a significant shift of the overall melting 
curve, though the change in Tm is more modest (observed Tm values of ~77 °C, ~79 °C, ~83 °C 
for 5-helix, GLUE-Cpep, and the complex, respectively). The melting transition for the 1:1 
sample is also highly cooperative, further supporting a well-defined assembly. 
2.6 GLUE-Cpep Binds 5-Helix in Complex Cellular Environments 
Having validated the GLUE-Cpep/5-helix interaction, we moved on to probe its viability in 
more complex environments. Binding in living cells (E. coli) was first assessed by split-
superpositive Green Fluorescent Protein (split-spGFP) reassembly, a technique we recently 
reported.19 E. coli were co- transformed with plasmids encoding 5-helix fused to the N- terminal 
half of spGFP (N-spGFP-5-helix) and one of two C-spGFP fusions: GLUE-Cpep or the gp41 C-
	 19	
peptide by itself. Interaction-dependent reassembly of GFP fragments (to generate a fluorescent 
signal) was measured by flow cytometry. Cells expressing either ligand construct are highly 
fluorescent, in contrast to a control with nothing fused to C-spGFP (Figure 2.3D). We further 
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Figure 2.3 (A) Depection of 5-helix, a single protein consisting of three copies of gp41 N-peptide (tan) 
and two copies of gp41 C-peptide (purple). When folded, this protein presents a single binding site for 
a C-peptide (or mimic thereof), which is depicted as a dashed column. (B) Cirular dichroism spectra of 
GLUE-Cpep (blue circles), 5-helix (red circles) and a pre-mixed 1:1 ratio of 5-helix-His and GLUE-Cpep 
(open circles) (C) Circular dichroism data (222 nm) showing temperature-dependent melting of the 
solutions in part (B). (D) Flow cytometry data of E. coli following split-spGFP reassembly experiments. 
Negative = NscGFP-5-helix/CscGFP-; Cpep = NscGFP-5-helix/CscGFP-C-pep; GLUE-Cpep = 
NscGFP-5-helix/CscGFP-GLUE-Cpep. (E) ELISA data from E. coli cell lystate that contain an empty 
pET DUET plasmid, or pET DUET that encodes-5-helix-His along with wtGLUE, GLUE-Cpep, or C-
peptide. (F) Co-purifciation of 5-helix-His and untagged GLUE-Cpep from E. coli cell lysate. 
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characterized this interaction using an Enzyme-Linked Immunosorbant Assay (ELISA). The 
grafted GLUE binds 5-helix with slightly better affinity than the native C-peptide (Figure 2.3E, 
columns 3 and 4, respectively), while the wild type GLUE exhibits no appreciable affinity 
(Figure 2.3E, column 2), confirming the need for the grafted domain. This ELISA signal is 
observed even for a GLUE-Cpep sample that was pre-incubated with human serum (Supporting 
Information), confirming that the degradation-resistant form of the protein remains functional. 
Taken together, these experiments show that the helix-grafted GLUE binds 5-helix in the context 
of a complex cellular milieu, in a manner comparable to the native ligand, and with improved 
serum longevity. 
 Binding selectivity was assessed by measuring the amount of protein that is co-purified 
from E. coli expressing an untagged GLUE-Cpep (~17.1 kDa) and 5-helix-His6 (~25.4 kDa). As 
seen in Figure 4F, the tagged 5-helix co-purifies with a single protein, which was identified as 
GLUE-Cpep by mass spectrometry (Supplemental Data, 2.1). The similar amounts of each co-
purified protein (as determined by densitometry measurements of each protein band) further 
indicates that the complex involves a 1:1 ratio of proteins. The relatively miniscule levels of 
other co-purified cellular proteins indicates excellent selectivity for this interaction, even in a 
complex cellular environment, suggesting a reasonably strong mutual affinity. 
 
2.7 Conclusion 
We have demonstrated that the solvent exposed C-terminal alpha helix of the GLUE 
protein scaffold can be dramatically modified and extended, so as to mimic the function of the 
gp41 C-peptide. ELISA and co-purification data indicate that GLUE-Cpep selectively binds 5-
helix, a protein that mimics the native C-peptide receptor. Unlike the isolated C-helix of 
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Enfuvirtide, GLUE-Cpep is soluble and well-folded in aqueous solution at room temperature 
(~25 °C), and is resistant to degradation in human serum at physiological temperature (~37 °C). 
Thus, this protein drug lead overcomes challenges faced by traditional peptide reagents and may 
represent a new reagent for inhibition of HIV entry. Additionally, helix-grafting onto PH and 
PH-like domains, such as GLUE, may be a general approach to the development of new reagents 
of interest to a diverse set of diseases that rely on helix-driven assembly. Finally, GLUE-Cpep 
serves as a starting point for the generation of higher affinity and more selective mutants through 
the application of high-throughput screening or selection methods. Such experiments are 
currently underway, and will be reported in due course. 
 
2.8 Methods 
Protein Expression and Purification Genes were cloned into pETDuet-1 using restriction 
enzymes BamHI and PacI, downstream of a His6 tag and transformed into BL21s (DE3). Cells 
were grown in 2.5 L LB cultures containing 50 µg/mL carbenicillin at 37 °C to OD600=0.5 and 
induced with 1 mM IPTG at 25 °C overnight. Cells were then collected by centrifugation, 
resuspended in Tris buffer (20 mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4) and stored at 
-20 °C. Frozen pellets were thawed and sonicated with 1 second pulses for 2 minutes. The lysate 
was cleared by centrifugation (15,000 rpm 30 min.) and the supernatant was mixed with 1 mL of 
Ni-NTA agarose resin for 1 hour at 4 °C. The resin was collected by centrifugation (4950 rpm, 
10 min.). The resin was sequentially washed with 50 mL of buffer containing 20 mM imidazole, 
10 mL buffer containing 50 mM imidazole, and 5 mL buffer containing 100 mM imidazole. The 
protein was then eluted with 4 mL buffer containing 400 mM imidazole. The proteins were 
dialyzed against Tris buffer and analyzed for purity by SDS-PAGE shown below. Purified 
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protein concentrations were quantified using Beer’s Law at an absorbance of 280nm, following 
standard practice. In general, GLUE-Cpep was expressed as a soluble protein (~3mg/L of E. coli 
culture). 
 
Resolublization from Inclusion Bodies 5 Helix-His was cloned into a modified pETDuet-1 
vector using restriction enzymes NdeI and KpnI and transformed into BL21s (DE3). Cells were 
induced to express 5 Helix-His and lysed as described above. The lysate was cleared by 
centrifugation (15,000 rpm, 30 min.) and the supernatant discarded. The pellet was washed twice 
with Tris buffer containing 0.5 % Triton® X-100 and once with Tris buffer. The pellet was 
resuspended in urea buffer (Tris buffer with 8 M urea and 10 mM imidazole) to resolubilize the 
inclusion bodies and cleared by centrifugation (9,500 rpm, 30 min.) The supernatant was mixed 
with 1 mL of Ni-NTA agarose resin for 1 hour at 4 °C. The resin was collected by centrifugation 
(4950 rpm, 4 min.). The resin was washed with 50 mL of urea buffer and eluted with 40 mL of 
urea elution buffer (Tris buffer with 6 M urea and 100 mM imidazole) into 500 mL Tris buffer 
by gravity dripping while stirring to refold the protein. The 540 mL elution was run through a 
column containing 1 mL of Ni-NTA agarose resin and eluted with 5 mL Tris buffer containing 
400 mM imidazole. The protein was then eluted with 4 mL buffer containing 400 mM imidazole. 
The proteins were dialyzed against buffer and analyzed for purity by SDS-PAGE and analyzed 
for refolding by CD. Purified proteins were quantified using Beer’s Law at an absorbance of 
280nm. 
 
Circular Dichroism Proteins were purified as described above. Separately, each protein was 
diluted to 7-9 µM in Tris buffer (20 mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4). 
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Wavelength data are the average of three scans from 250 nm to 200 nm in 1 nm steps at 25 °C. 
Thermal denaturation experiments at 222 nm were run from 0 to 90 °C in two-degree steps at a 
two-degree/minute rate of increase with one-minute equilibration and data averaging at each 
temperature. Tm values were obtained from minima of the first derivative of θ versus 1/T plots.  
 
Serum Stability Assay Using a previously described assay for serum stability, GLUE-Cpep was 
cloned into pET-28a(+) with an N-terminal FLAG tag using restriction enzymes NdeI and 
HindIII. The completed construct was transformed into BL21s (DE3) and purified as described 
previously. 1 mL of RPMI supplemented with 25% (v/v) of human serum was equilibrated at 37 
°C. GLUE-Cpep was added to the solution to obtain a final concentration of 50 µg/mL and 
incubated at 37 °C. At known time intervals of 0.5, 1, 2, 4, 8, or 12 hours, 100 µL of the reaction 
solution was removed and denatured at 94 °C for 20 minutes and stored at -80 °C. Samples were 
separated by SDS-PAGE and transferred to a nitrocellulose membrane via an iBlot western 
blotting apparatus. The membrane was washed with PBS and incubated in LI-COR Blocking 
Buffer at 4 °C for 1 hr. The membrane was then incubated with a mouse anti-DDDDK antibody 
(anti-FLAG) in LI-COR Blocking Buffer for 1 hr at 4 °C. The membrane was washed 3x with 
PBS containing 0.1 % Tween-20, and then incubated with a IRDye 800CW Goat anti-mouse 
IgG-LI-COR secondary antibody in LI-COR Blocking Buffer for 1 hr at room temperature. The 
membrane was washed 3x with PBS containing 0.1 % Tween-20 and imaged using the Odyssey 
Classic Infrared Imager.  
 
Split-Superpositive GFP (split-spGFP) Reassembly Assay Split-spGFP reassembly 
experiments were performed as previously described. N-terminal superpositive GFP tethered to 
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the 5-helix was cloned into pETDuet using restriction enzymes BamHI and PacI. The completed 
construct was transformed into BL21s (DE3) and the cells were made electrocompetent via 
standard protocols. Separately, GLUE-Cpep and C-peptide tethered to the C-terminal fragment 
of superpositive GFP were independently cloned into pBAD using restriction enzymes NcoI and 
BsrGI. Constructs were electroporated into electrocompetent BL21s (DE3) containing the N-
terminal superpositive GFP plasmid, pulsing at 1.8 kV in a 1 mm cuvette. Cells were allowed to 
recover at 37 °C for 1 hr, and then plated onto agar plates containing carbenicillin and 
kanamycin. Individual colonies were picked and passaged once, followed by induction at 37 °C 
with 1 mM IPTG and 0.2% arabinose when cultures reached an OD600 of 0.5. After 6 hours, cells 
were spun down and resuspended in 5 mL PBS. GFP fluorescence was measured by MoFlo Flow 
Cytometer. 
 
ELISA Separately, wt-GLUE, GLUE-Cpep, and the C-peptide were cloned into MCS1 of 
pETDuet-1 with FLAG tags using restriction enzymes NcoI and NotI. The 5-helix with a C-
terminal His6 tag was cloned into MCS2 of pETDuet-1 using restriction enzymes NdeI and 
KpnI. Completed constructs were transformed into BL21s (DE3). Cells containing the co-
expressed pair were inoculated and induced as described previously. Cells were spun down and 
resuspended in lysis buffer (20 mM Hepes pH 7.5, 100 mM NaCl), lysed by sonication, and spun 
down to remove cell debris. Cleared lysates were incubated on clear Ni-NTA coated plates for 1 
hr at room temperature and washed 4x with 200 µL wash buffer (20 mM Hepes pH 7.5, 150 mM 
NaCl, 0.05% Tween-20, 0.01 mg/mL BSA). HRP-conjugated mouse anti-DDDDK antibody in 
LiCor Blocking Buffer was incubated for 1 hr at room temperature, followed by 4x 200 µL 
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washes. Colorimetry was developed using TMB-One substrate and absorbance was measured at 
655 nm on a SynergyMx Microplate Reader. 
 
ELISA Binding Assay in Human Serum GLUE-Cpep was cloned into pET-28a(+) with an N-
terminal FLAG tag using restriction enzymes NdeI and HindIII. 5-helix was cloned into 
pETDuet with an N-terminal AviTag and a C-terminal His6 tag using restriction enzymes NcoI 
and PacI. The completed constructs were transformed into BL21s (DE3) and purified as 
described previously. AviTag-5 helix was conjugated to biotin using Avidity BioMix protocols 
and purified BirA Protein Ligase at 1.0 mg/mL. Biotin conjugation was confirmed by Mass 
Spectometry. Separately, 5 mL of RPMI supplemented with 25% (v/v) human serum, 5 mL of 
boiled RPMI supplemented with 25% (v/v) of human serum, and 5 mL of (1x) PBS were 
equilibrated at 37 °C. GLUE-Cpep was added to each solution to a final concentration of 50 nM, 
and incubated at 37 °C for 4 or 12 hours. 200 µL wash buffer (1x PBS pH 7.4, 0.1% Tween-20, 
0.02 mg/mL BSA) was incubated on clear streptavidin coated plates for 1 hr at room temperature 
to block. 100 µL of Biotinylated 5-helix at a concentration of 10 µg/mL was incubated for 1 hr at 
room temperature and washed 4x with 200 µL wash buffer. 100 µL of human serum-incubated 
GLUE-Cpep solutions were incubated on the plates for 1 hr at room temperature and washed 4x 
with 200µL wash buffer. HRP-conjugated mouse anti-FLAG antibody in LiCor blocking buffer 
was incubated for 1 hr at room temperature, followed by 5x 200 µL washes. Colorimetry was 
developed using TMB-One substrate and absorbance was measured at 655nm on a SynergyMx 
Microplate Reader. These ELISA data can be found in Figure S3. 
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Lysate Ni-NTA Pulldown Assay GLUE-Cpep was cloned into MCS1 of pETDuet-1 using 
restriction enzymes NcoI and NotI. The 5-helix with a C-terminal His6 tag was cloned into 
MCS2 of pETDuet-1 using the restriction enzymes NdeI and KpnI. Completed constructs were 
transformed into BL21s (DE3). Cells containing the co-expressed pair were inoculated and 
induced as described previously. Cells were spun down and resuspended in lysis buffer (100 mM 
NaCl, 20 mM Tris pH 7.4, 10 mM (NH4)2SO4), lysed by sonication, and spun down to remove 
cell debris. Cleared lysate was incubated with 200 µL Ni-NTA agarose resin for 1 hour. Ni-NTA 
agarose was washed with 8 mL lysis buffer and with 10 mM imidazole. Proteins were eluted 
with 500 µL lysis buffer containing 400 mM imidazole. The pulldown was analyzed by SDS-
PAGE and confirmed by Mass Spectroscopy.	 
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 In this work, I designed the helix grafting strategies, as well as carried out molecular 
cloning and protein purifications. I also performed all circular dichroism, cell lysate ELISAs and 
co-purification experiments. Susanne Walker, a fellow graduate student, assisted in the helix 
grafting design and measured the KD of our best helix grafting proteins via ELISA. Terumasa 




Chapter II describes using a PH domain from a yeast-derived protein called GLUE as a 
scaffold for gp41 C-peptide helix-grafted display. Surface-exposed GLUE helix residues were 
mutated to match those of gp41, and the helix was extended to match the native C-peptide length 
using the pure gp41 sequence. The resulting grafted protein was shown to be stable, well folded, 
and capable of recognizing a standard gp41 model with fidelity comparable to that of the wild-
type peptide as measured by split-GFP reassembly, ELISA, and copurification assays. It also 
retained much of its efficacy even after 12 hours of exposure to human serum, supporting our 
initial design hypothesis that positioning the ligand within a larger stably folded structure would 





This chapter was adapted from:  
Tennyson, R. L.;  Walker, S. N.;  Ikeda, T.;  Harris, R. S.;  Kennan, A. J.; McNaughton, B. R., 
Helix-Grafted Pleckstrin Homology Domains Suppress HIV-1 Infection of CD4-Positive Cells. 	
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3.3 Pleckstrin Homology Domains: A General Scaffold for Helix Grafting  
Although the initial effort was quite successful, we were interested both in probing the 
scope of our chosen scaffold and in testing our gp41 mimics in more demanding environments. 
We began by selecting a collection of nine PH domains, favoring those of human origin to 
potentially mitigate downstream immunogenicity. The set of PH domains with reported X-ray 
structures exhibit considerably diversity in helix length, total protein size, and percentage of total 
residues involved in the helix.
2-9
 Since we were unsure how each of these variables might impact 
expression viability and/or helix presentation, we chose an array of candidates covering a range 
of characteristics (Figure 3.1A, Supporting Information Table S3.1). While the canonical PH 
fold presents a C-terminal helix, the Engulfment and Cell Motility (ELMO)-1 domain has the 
added benefit of an additional N-terminal helix, providing the option to display partially 
structured ligands that are helical only at one terminus.  
Our initial screen for scaffold suitability was simple expression of the wild-type proteins, 
since well-expressing systems were expected to better tolerate modification. At this stage, four of 
our nine next generation candidates were eliminated based on poor expression (Figure 3.2A, 
Supporting Information, Figure S3.1). The remaining ones, including our original GLUE 
scaffold, were grafted with the gp41 C-peptide sequence. We tested both the N- and C-terminal 
ELMO sites, and were satisfied to discover that both constructs expressed admirably (Figure 
3.2B, Supporting Information, Figure S3.1). Although other sequences also worked, ELMO 
seemed to present the most flexibility and thus the most potential to serve as a general scaffold 




3.4 Helix Grafted ELMO 
Having centered on ELMO as our most promising display vehicle, we sought to test its 
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Figure 3.1 (A) Candidate PH domain scaffolds examined in this work. PDB: 1P6S (AKT2), 2ELA (APPL1 
PH), 2ELB (APPL1 PTB), 1J0W (DOK5), 2DYN (DYNAMIN), 1I2H (HOMER), 2VSZ (ELMO),1UNP 
(PKB), and 2I5F (PLECKSTRIN). Not shown: 2CAY (GLUE). (B) Expression levels of soluble wild type 




the sensitivity of our grafted constructs to alterations in ligand sequence. Although the C34 
peptide used in our original helix-grafted ligand is taken from the same region of gp41 as 
enfuvirtide (T-20), a significant portion of each sequence is unique. We thus sought to test both 
sequences, in addition to the longer one formed by their union (C46, Figure 3.2B, Figure 3.2C).  
To test the intrinsic flexibility of N- versus C-terminal display, we prepared ELMO scaffolds 
grafted at either terminus (Lig-ELMO or ELMO-Lig) with C34, T-20, and C46. We were 
especially interested to probe the role of the N-terminal WWI triad on C34, whose sidechains 
















Figure 3.2 (A) Soluble expression levels (following purification by His6/nickel NTA column purification) 
of selected scaffolds from Figure 2 with C-terminal C34 helix grafts, along with the N-terminal C26-
ELMO graft. Error bars indicate standard deviation of three measurements. The N- and C-terminus of 
ELMO is labeled for clarity. (B) Models of N-terminal (C26-ELMO) and C-terminal (ELMO-C34) helix 
grafts on the ELMO scaffold. Helix grafted display strategy on the N- and C-terminal helix of ELMO 
(spheres indicate alpha carbon positions). (C) Sequence of ligand mimic region for N- and C-terminal 
helix-grafted ELMO (designated L-ELMO and ELMO-L, respectively). 
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absence of this interaction in T20 (whose sequence is shifted more toward the C-peptide C-
terminus) perhaps reduces barriers to acquired resistance. 
The C-terminal grafts were prepared as before, with 5 solvent-exposed positions on the 
native ELMO helix mutated to correspond to those of the HIV sequence, and the C-terminus of 
the protein extended the appropriate amount using the pure gp41 sequence. In contrast to the C-
terminal ELMO helix, which rests atop the beta sheets, the N-terminal one is more fully exposed, 
and of considerable length (nearly 20 residues). Fearing that long extensions of this helix might 
not be well tolerated, we prepared C34-ELMO and T20-ELMO by first excising 17 residues 
from the native helix, and then simply fusing the appropriate sequence to the N-terminus of the 
resulting protein (termed Δ17-ELMO). For C46-ELMO 3 additional residues were trimmed 
(since the fused helix is longer). Finally, as a hedge against even these shorter helices proving 
unworkable, we prepared C26-ELMO, in which 8 residues were deleted from the C-terminus of 
C34 before fusing it to the shortened Δ17-ELMO scaffold. To determine the impact of the N-
terminal deletions from the core ELMO protein, we prepared both Δ17-ELMO and Δ21-ELMO 
on their own, and were pleased to discover that both expressed even better than the wild-type 
platform (Supporting Information, Figure S3.2), so much so that we used Δ21-ELMO as the 
starting point for the ELMO-Lig constructs. 
 
3.5 Characterizing Helix Grafted ELMO Proteins 
To establish that these various modifications had not compromised the overall protein 
fold, we examined each grafted protein using circular dichroism (CD) spectroscopy, and 
compared the results to those of the base proteins (wild type, Δ17-, and Δ21-ELMO). Plots of 
mean residue ellipticity versus wavelength for the C-terminal fusions are consistent with 
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retention of overall structure, and display expected helicity increases compared to the appropriate 
control (Figure 3.3A). Similarly, the N-terminal fusions all exhibit increased helicity with 
respect to each of the starting proteins (Figure 3.3B). The helix-grafted proteins also display 
similar thermal unfolding profiles, consistent with retention of macroscopic structure 
(Supporting Information, Figure S3.3). Having determined that the HIV ligand mimic 
candidates were behaving as expected, we moved on to evaluate their viability as ligands for 
both model and live-virus receptors. 
Figure 3.3 (A) Circular dichroism spectra of C-terminal (A) and N-terminal (B) ELMO grafts. (C) A 
cartoon representation of 5-helix, a single polypeptide that contains the NTR trimer (tan), as well as two 
C-peptides (purple). (D) ELISA data showing binding between 5-helix-His6 and ELMO-derived grafted 
proteins. (E) Nickel-NTA co-purification of 5-helix-His and either N-terminal (top) or C-terminal (bottom) 
helix-grafted ELMO-derived proteins. (Dissociation constant (KD) for complexes involving 5-helix and (F) 
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Just as Chapter II describes, initial evaluations of ligand/receptor binding employed the 
5-helix construct that has been widely used for this purpose.
10, 11
 The 5-helix protein links gp41’s 
central coiled-coil N peptide trimer and two C peptide ligands into one sequence that assembles 
to present a single C-peptide binding site. This strategy both simplifies the interaction to be 
measured (making it a 1:1 rather than 3:1 complex), and eases solubility issues arising from 
exposing three copies of the significantly hydrophobic ligand binding surface (Figure 3.3C).  
We initially performed an ELISA assay to verify binding. Somewhat surprisingly, the 
native N-helix on ELMO, which we originally feared might compromise expression efficiency, 
also has some non-specific affinity for 5-helix, at least in this assay. However, this non-specific 
binding can be abbrogated by truncation of the N-terminal helix. Two shortened variants, Δ17-
ELMO and Δ21-ELMO (where 17 or 21 residues were removed from the N-terminal helix 
respectively), show substantially decreased affinity for 5-helix in ELISA (Figure 3.3D). The N-
terminal fusions generate stronger signals, particularly those with the WWI residues: C26-ELMO 
and C34-ELMO are better than C46-ELMO, which in turn is better than T20-ELMO.  The two 
shorter fusions give signals comparable to the native C34 peptide. The C-terminal fusions were 
weaker, with only Δ21-ELMO-C34 giving a signal even comparable to the analogous control 
scaffold (Δ21-ELMO).  
We next examined the ability of each grafted or control protein to bind 5-helix in the 
complex environment of E. coli. Cells were transformed with a plasmid encoding both the ligand 
candidate and His-tagged 5-helix, lysed, and exposed to Ni-NTA agarose resin. Consistent with 
data points in our ELISA experiment (Figure 3.3D), SDS-PAGE analysis of the N-terminal 
fusions (Figure 3.3E, lanes 1-6) suggested that those bearing the WWI triad (lanes 3-5) were 
most effective at binding to 5-helix. The two shorter helices (C26- and C34-) displayed the 
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strongest retention, with a significant reduction for the longer C46-ELMO construct, and very 
little observable retention for T20-ELMO. The C-terminal fusions (Figure 3.3E, lanes 7-12) 
exhibit a similar trend, albeit with an overall reduction in apparent affinity. Comparing those 
with the native N-helix removed (Δ21-ELMO-Lig), the C34 fusion (lane 10) is again more 
effective, though the intact ELMO-C34 protein (lane 9) is perhaps even better. Both truncations 
(Δ17 and Δ21 ELMO do not appreciably bind 5-helix in the co-purification assay (Figure 3.3E) 
To better understand the complex involving 5-helix and our best performing binders 
(C26-ELMO and C34-ELMO), we used ELISA to measure their dissociation constants (KD). 
Satisfyingly, these proteins tightly bind 5-helix (KD ~ 90 ±8 nM and 6 ±2 nM, respectively, 
Figure 3.3F and Figure 3.3G). In addition to tightly binding 5-helix, C26-ELMO and C34-
ELMO are relatively stable in proteolytically active human serum. For both proteins, >50% of 
the full-length species was detected by Western blot after incubating with proteolytically active 
human serum for 12 hours (Supporting Information, Figure S3.4). 
 
3.6 ELMO Suppresses HIV-1 Infection in a Live Virus Assay 
Collectively, these initial experiments supported the notion that C-peptide grafted ELMO 
scaffolds were capable of recognizing the 5-helix model system in even complicated cellular 
contexts, and further suggested that the most efficient of these systems were the shorter N-
terminal fusions bearing the key WWI residues. Encouraged by these data, we set out to test the 
ability of helix-grafted gp41 mimics to inhibit infection by actual virus, using a previously 
reported protocol.
12, 13
 HIV-1 IIIB was administered to CD4-positive mammalian cells stably 
integrated with a plasmid that encodes the HIV-1 long-terminal repeat (LTR) upstream of GFP. 
Thus, if HIV-1 successfully infects these cells, HIV-1 Tat/TAR-dependent transcription 
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ultimately leads to GFP expression. The percentage of cells that express GFP (measured by flow 
cytometry) is thus equivalent to the percentage infected by the virus.  Consistent with the ELISA 
and co-purification experiments, the N-terminal fusions proved more effective by this measure as 
well (Figure 5A). Only the three WWI-containing helices (C26-, C34-, and C46-ELMO) 
exhibited significant inhibition, with the T20-ELMO protein proving largely ineffective. The 
longer C46 construct again lagged behind the shorter helices, despite containing the WWI triad. 
The C-terminal fusions (Figure 5B), as before, were overall less efficient, and only Δ21-
ELMO-C34 was comparable to any of the N-terminal species. The scaffold controls (Δ17- and
Δ21-ELMO) did not materially inhibit infection, despite ELISA data suggesting at least 
moderate 5-helix affinity. Although both N- and C-terminal T20 fusions were largely ineffective 
in each of these assays, the isolated T20 peptide itself is significantly more potent in the live 
virus assay than any of our grafted systems. However, this in vitro assay is blind to the rapid 



















































































Figure 3.4. (A) Suppression of HIV-1 entry by ELMO-derived C-terminal fusions Δ21 ELMO (black); 
T20 peptide (purple); Δ21 ELMO-C34 (red); D21 ELMO-C46 (orange); D21 ELMO-T20, (green). (B) 
Suppression by N-terminal fusions Δ17 ELMO (gray); Δ21 ELMO (black); C26 ELMO (red); C34 




Taken together, these results demonstrate the viability of our helix-grafting strategy as a 
method for presenting gp41 C-peptide helices in a manner that allows them to efficiently 
recognize their intended receptor. Despite this success, opportunities for improvement remain. 
One plausible explanation for reduced efficacy of the longer C46 constructs (compared to 
C26/C34) is steric crowding, especially in the more complex in cellulo experiments with 
proximal lipid bilayers. It may be that further reduction in scaffold size is required for true 
generality moving forward.  Additional affinity may also be obtained through directed evolution, 
optimizing the choice of receptor-facing residues. Experiments along both these lines are 
underway. In the longer term, we are confident that the general strategy of helix-grafted ligand 
display platforms will prove amenable to the discovery and optimization of new PPI ligands for 
many different targets. 
 
3.8 Methods 
Protein Expression and Purification Genes were cloned into pET using restriction enzymes 
BamHI and KpnI, downstream of a His6 tag and transformed into BL21s (DE3). Proteins 
containing a disulfide bond were transformed into SHuffle T7s. Cells were grown in 0.5 L LB 
cultures containing 50 mg/mL carbenicillin at 37 °C to OD600 =0.5 - 0.6 and induced with 1 mM 
IPTG at 25 °C overnight. Cells were then collected by centrifugation, resuspended in Tris buffer 
(20 mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4) and stored at -20 °C. Frozen pellets 
were thawed and sonicated with 1 second pulses for 2 minutes. The lysate was cleared by 
centrifugation (8,000 rpm 10 min.) and the supernatant was mixed with 1 mL of Ni-NTA agarose 
resin for 30 min at 4 °C. The resin was collected by centrifugation (4950 rpm, 10 min.). The 
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resin was sequentially washed with 50 mL of Tris buffer containing 20 mM imidazole, 50 mL 
buffer containing 50 mM imidazole, and 10 mL Tris buffer containing 75 mM imidazole. The 
protein was then eluted with 2 mL Tris buffer containing 400 mM imidazole. The proteins were 
dialyzed against Tris buffer and analyzed for purity by SDS-PAGE shown below. Purified 
protein concentrations were quantified using Beer’s Law at an absorbance of 280 nm, following 
standard practice. 
 
Resolublization of 5-Helix Inclusion Bodies 5 Helix-His6 was cloned into a modified pETDuet-
1 vector using restriction enzymes NdeI and KpnI and transformed into BL21s (DE3). Cells were 
induced to express 5 Helix-His6 and lysed as described above. The lysate was cleared by 
centrifugation (9,500 rpm, 30 min.) and the supernatant discarded. The pellet was washed twice 
with Tris buffer containing 0.5 % Triton® X-100 and once with Tris buffer. The pellet was 
resuspended in urea buffer (Tris buffer with 8 M urea and 10 mM imidazole) to resolubilize the 
inclusion bodies and cleared by centrifugation (9,500 rpm, 30 min.) The supernatant was mixed 
with 1 mL of Ni-NTA agarose resin for 1 hour at 4 °C. The resin was collected by centrifugation 
(4950 rpm, 4 min.). The resin was washed with 50 mL of urea buffer and eluted with 40 mL of 
urea elution buffer (Tris buffer with 6 M urea and 100 mM imidazole) into 500 mL Tris buffer 
by gravity dripping while stirring to refold the protein. The 540 mL elution was run through a 
column containing 1 mL of Ni-NTA agarose resin and eluted with 5 mL Tris buffer containing 
400 mM imidazole. The protein was then eluted with 4 mL buffer containing 400 mM imidazole. 
The proteins were dialyzed against buffer and analyzed for purity by SDS-PAGE and analyzed 
for refolding by CD. Purified proteins were quantified using Beer’s Law at an absorbance of 280 
nm. 
	 42	
Circular Dichroism Proteins were purified as described above. Separately, each protein was 
diluted to 5-12 µM in Tris buffer (20 mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4). 
Wavelength data are the average of three scans from 250 nm to 200 nm in 1 nm steps at 25 °C. 
Thermal denaturation experiments at 222 nm were run from 0 to 90 °C in two-degree steps at a 
two-degree/minute rate of increase with one-minute equilibration and data averaging at each 
temperature. Tm values were obtained from minima of the first derivative of θ versus 1/T plots.  
 
Serum Stability The helix-grafted C26-ELMO and C34-ELMO protein were cloned into a 
pETDUET upstream of a C-terminal His6-GS-FLAG tag (DYKDDDDK). Proteins were purified 
as described above in Phosphate buffer (20 mM Na2HPO4 pH 7.4, 100 mM NaCl). 1 mL of 
RPMI supplemented with 25 % (v/v) of human serum was equilibrated at 37 °C. C26-ELMO and 
C34-ELMO were each added to the solution to obtain a final concentration of 50 µg/mL and 
incubated at 37 °C. At known time intervals of 0.5, 1, 2,4, 8, 12, 24 hours, 100 µL of the reaction 
solution was removed and denatured at 94 °C for 20 minutes and stored at -80 °C. Samples were 
separated by SDS-PAGE and transferred to a nitrocellulose membrane via an iBlot western 
blotting apparatus. The membrane was washed with TRIS and then incubated in Blocking Buffer 
at room temperature for 1 hour. The membrane was subsequently washed 3x with TRIS 
containing 0.1 % Tween® 20. The membrane was then incubated with a mouse anti-FLAG 
antibody in primary antibody wash buffer (TRIS with 5% BSA and 0.1 % Tween® 20) for 3 
hour at 4 °C. The membrane was then washed 3x with TRIS containing 0.1 % Tween® 20, and 
then incubated with a IRDye 800CW Goat anti-mouse IgG secondary antibody in Blocking 
Buffer for 1 hour at room temperature. The membrane was washed with PBS containing 0.1 % 
Tween-20 and imaged using the Odyssey Classic Infrared Imager. 
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Cell lysate ELISA Each helix grafted ELMO protein, T20, and C34 were cloned into MCS1 of 
pETDuet-1 with FLAG tags using restriction enzymes NcoI and NotI. The 5-Helix with a C-
terminal His6 tag was cloned into MCS2 of pETDuet-1 using restriction enzymes NdeI and KpnI. 
Completed constructs were transformed into BL21s (DE3). Cells containing the co-expressed 
pair were inoculated and induced in 10 mL LB cultures overnight. Cells were spun down and 
resuspended in 10 mL buffer (20 mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4), lysed by 
sonication, and spun down to remove cell debris. Cleared lysates were incubated on clear Ni-
NTA coated plates for 1 hr. at room temperature and washed 3x with 200 µL wash buffer (20 
mM Tris pH 7.4, 100 mM NaCl, 10 mM (NH4)2SO4, 0.1% Tween® 20, 0.01 mg/mL BSA). 
HRP-conjugated mouse anti-DDDDK antibody in LiCor Blocking Buffer was incubated for 1 hr 
at room temperature, followed by 3x 200 µL washes (5 min.). Color was developed using TMB-
One substrate and absorbance was measured at 655nm on a SynergyMx Microplate Reader.  
 
Lysate Ni-NTA Pulldown Assay Each protein was cloned into MCS1 of pETDuet using 
restriction enzymes NcoI and NotI. The 5-helix with a C-terminal His6 tag was cloned into 
MCS2 of pETDuet using the restriction enzymes NdeI and KpnI. Completed constructs were 
transformed into BL21s (DE3). Cells containing the co-expressed pair were inoculated and 
induced in 100 mL LB cultures overnight. Cells were spun down and resuspended in 5 mL buffer 
(100 mM NaCl, 20 mM Tris pH 7.4, 10 mM (NH4)2SO4), lysed by sonication, and spun down to 
remove cell debris. Lysate was incubated with 300 µL Ni-NTA agarose resin for 30 min. The 
resin was collected by centrifugation (4950 rpm, 10 min.). The resin was sequentially washed 
with 10 mL of Tris buffer containing 50 mM imidazole and 5 mL Tris buffer containing 100 mM 
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imidazole. Proteins were eluted with 500 µL Tris buffer containing 400 mM imidazole.  
Biotinylation 5-helix-His was cloned into a pET vector containing an upstream Avitag™ 
(GLNDIFEAQKIEWHE)-GGSGGSGGT linker using restriction enzymes KpnI and PacI. The 
protein was resolublized from inclusion bodies as described above in Phosphate buffer (20 mM 
Na2HPO4 pH 7.4, 100 mM NaCl). His-BirA was cloned into pET using restriction enzymes NcoI 
and KpnI and purified as described above in Phosphate buffer. 300 µL of Avitagged™ 5-helix-
His protein at 38 µM was incubated with 6 µL of His-BirA at 1 mg/mL using Avidity® BirA 
biotin-protein ligase standard reaction kit at 30°C for 40 min. Biotinylation was confirmed by 
Agilent 6220 TOF LC-MS.  
 
In vitro ELISA The helix-grafted C26-ELMO protein and helix-grafted C34-ELMO protein 
were cloned into a pET vector upstream of a C-terminal His-GS-FLAG tag (DYKDDDDK) 
using restriction enzymes NheI and BamHI. Proteins were purified as described above in 
Phosphate buffer (20 mM Na2HPO4 pH 7.4, 100 mM NaCl). The biotinylated Avi-tagged 5-
helix-His6 (biotin-5-helix-His) was prepared as described above in Phosphate buffer and diluted 
to 10 mg/mL. Pierce® Streptavidin coated clear 96-well plates with a binding capacity of 5 pmol 
were pre-blocked with 200 µL of wash buffer (Phosphate buffer, 0.5 mg/mL BSA, 0.1% tween® 
20) for 1 hour. Biotin-5-helix-His was immobilized on the streptavidin-coated plates by 
incubating 100 µL of diluted protein for 1 hour at room temperature, followed by 4x 200 µL 
washes (5 min). 100 µL of C26-ELMO or C34-ELMO was incubated in various concentrations 
(10 pM, 100 pM, 1 nM, 5 nM, 10 nM, 20 nM, 25 nM, 30 nM, 50 nM, 75 nM, 100 nM, 200 nM, 
500 nM, 750 nM, 1 µM, 10 µM) for 1 hour, followed by 4x 200 µL 4°C washes (5 min). (All 
concentrations of incubated helix-grafted protein were above ligand-depleting conditions for 
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binding the 5 pmol immobilized biotin-5helix in each well). A 1:10,000 dilution of HRP-
conjugated mouse anti-DDDDK antibody in LiCor Blocking Buffer was incubated for 1 hour at 
room temperature, followed by 4x 200 µL 4°C washes (5 min). Color was developed using 
TMB-One substrate and absorbance was measured at 655nm on a SynergyMx Microplate 
Reader.  
 
Infectivity Assay HEK293T cells were maintained in DMEM supplemented with 10% fetal 
bovine serum (FBS) and 0.5% penicillin/streptomycin (P/S). CEM-GFP cells were cultured in 
RPMI with 10% FBS and 0.5% P/S. The procedure was virtually identical to a previously 
published variant. The HIV-1 IIIB C200 proviral expression construct has been described 
previously. Viruses were produced by transfection of 3.0 µg of Vif-proficient proviral expression 
construct into 293T cells (3.0x10
6
) using TransIT -LT1 reagent. 48 hr later, virus-containing 
supernatants were filtered by 0.45 µm filters and used to infect into 2.5x10
4
 CEM-GFP cells with 
varying concentration of inhibitors. Infectivity (GFP
+
 cells) was measured by flow cytometry at 
2 days post-infection. 
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We have used helix-grafted display to create proteins capable of suppressing HIV entry.
1, 2
 
This therapeutic activity is the result of inhibiting an intramolecular PPI between HIV-1 gp41 C-
peptides (α-helix) and a trimer of HIV-1 gp41 N-peptides, which contain C-peptide α-helix-
binding clefts as described in Chapter I. Helix-grafted proteins presenting a C-peptide surrogate 
bind pre-fusogenic gp41 N-peptide trimer, leading to suppression of gp41 fusogenic assembly. 
Our second-generation helix grafted protein, Cpep-ELMO, consists of the ELMO scaffold (with 
a truncated N-terminal helix) and a genetic fusion between the N-terminal ELMO helix and gp41 
C-peptide (Figure 4.1A). Cpep-ELMO binds tightly to gp41 5-helix (KD ~ 90 nM) and 





This chapter was adapted from:  
Tennyson, R. L.;  Walker, S. N.;  Ikeda, T.;  Harris, R. S.; McNaughton, B. R., Evaluation of 
sequence variability in HIV-1 gp41 C-peptide helix-grafted proteins. Bioorg Med Chem 2018, 26 
(6), 1220-1224.	
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contrast to its peptide counterpart (the FDA approved peptide drug Fuzeon™), Cpep-ELMO is 
stable in human serum. 
During the course of these earlier studies, we questioned whether or not the gp41 C-peptide 
helix could be evolved for improved function, within the context of helix-grafted display. We 
reasoned that mutation and optimization of solvent-exposed residues on the grafted C-peptide 
helix could result in improved N-peptide trimer recognition, improved expression, and/or 
improved stability of the helix-grafted protein. Additionally, we reasoned that mutating solvent 
exposed C-peptide residues, and evaluating this protein library for target affinity, would provide 
valuable information on the relative role each mutated C-peptide residue plays in gp41 N-peptide 
trimer recognition, and the capacity for variation within this helix. With this in mind, we set out 
to create a Cpep-ELMO library, with randomized solvent exposed residues in the grafted helix, 
and use yeast display to evaluate this helix-grafted display protein library for N-peptide trimer 
recognition. 
 
4.2 Yeast Display Evolution of a Cpep-ELMO Helix-Grafted Display Protein Library 
As stated above, we first demonstrated that we could graft a portion of gp41 C-peptide onto 
ELMO, to generate a new protein that reliably replicates C-peptide display and suppresses HIV-1 
entry.
2
 We next sought to evaluate sequence variability in the grafted helix. Five positions on 
Cpep-ELMO (Figure 4.1A) that bury into the C-peptide helix-binding cleft of N-peptide trimer 
(wild-type sequence WWIYI) were randomized by saturation mutagenesis. In particular, the 
tryptophan residues (labeled residues 1 and 2 in Figure 4.1A) we mutated are buried in a deep 




. Thus, these mutations, in a sense, serve as a control for amino acid evolution (‘hits’ 
should regain those tryptophan residues). 
The ~3.2 million member Cpep-ELMO derived protein library was displayed on yeast, and 
tightest binders were selected by cell sorting. Specifically, the yeast display library was made to 
express Cpep-ELMO derived library members that contain an C-terminal cMyc tag. Following 
display, yeast was concomitantly incubated with a FITC-labelled anti-cMyc antibody and 
biotinylated gp41 5-helix. 5-helix is a previously reported protein that covalently tethers five of 
the six subunits within the gp41 trimer-of-hairpins (three N-peptides and two C-peptides) using 
simple GlyGlySer connectors.
4, 5
 When folded, it features the gp41 coiled coil with two of its 
binding sides already occupied, and just a single exposed interface (Figure 4.1B). This reduces 
the recognition event to a simple 1:1 interaction, simplifying the analysis. Following a brief 
washing step, streptavidin-phycoerythrin conjugate (SA-PE) was added. Thus, yeast displaying 
biotin, by virtue of a surface protein/5-helix interaction, will be bound by SA-PE. Yeast were 
then analyzed by flow cytometry, and sorted for the highest FITC fluorescence intensity (which 
comments on display efficiency) and PE red pigment intensity (which comments on 5-helix 





























































Figure 4.1. (A) Library design for Cpep-ELMO helix-grafted display library. Residues labeled 1-5, and 
highlighted as light brown spheres, were mutated to all possible 20 proteinogenic amino acids, 
generating a ~3.2 million-member protein library. (B) Cartoon depiction of gp41 5-helix, a single 
polypeptide that contains three N-peptides (brown) and two C-peptides (blue), which presents a 
single available C-peptide binding site. (C) Flow cytometry enrichment scheme to identify novel 
Cpep-ELMO helix-grafted proteins that bind to gp41 5-helix. (D) Flow cytometry data from yeast 
display library screening (round 1: left; round 2: right). Yeast selected in round 1 and round 2, 
representing 0.4% and 1% of the total population, respectively, are boxed. (E) Sequence logo 




were enriched by flow cytometry over the course of two rounds of screening against 500 nM or 
100 nM biotinylated 5-helix, respectively (Figure 4.1D). 
From our flow cytometry experiments, we identified eleven unique sequences that retain 
affinity for 5-helix in our yeast display screen. The established preference for tryptophan at 
positions W1 and W2 (Figure 4.1A) was faithfully replicated, suggesting that the method is 
sensitive to tightest receptor affinity. Meanwhile, while hydrophobic residues were often selected 
for, the other positions interrogated in this study are reasonably amenable to mutation, 
supporting the idea that variation within certain residues on the binding interface is permitted 
(Figure 4.1E). We next evaluated the effect helix mutations have on structure, expression, 
stability, function (5-helix recognition), and suppression of HIV-1 entry in a live virus assay. 
 
4.3 Evolved Cpep-ELMO Mutants Retain Affinity for HIV-1 gp41 5-helix 
Given the findings from our yeast display screening, whether or not solvent exposed residues 
on the gp41 C-peptide helix are amenable to mutation is no longer in question. What remained a 
question, however, was what effect these mutations had on the affinity for gp41 5-helix. We 
assessed binding between Cpep-ELMO mutants and gp41 5-helix by Enzyme-Linked 
Immunosorbent Assay (ELISA). 
Biotinylated gp41 5-helix was first immobilized onto commercially available streptavidin 
coated plates, which were then washed to remove unbound protein. Enriched mutants (Cpep1-
ELMO – Cpep11-ELMO) containing a C-terminal FLAG tag were separately incubated with 
immobilized 5-helix and binding as then analyzed by measuring luminescence, following 
incubation with necessary ELISA reagents. Of the initial eleven hits, five proteins (Cpep1, 3, 4, 
5, 8-ELMO) compared favorably to Cpep-ELMO and warranted further investigation (Figure 
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4.2A). Amino acid composition of Cpep-ELMO, and our evolved proteins at mutated positions is 
shown in Figure 4.2B. 
 
4.4 Evolved Cpep-ELMO Proteins are Structured, Stable, and Express Well in E. coli 
Given the findings from our yeast display screening and ELISA experiments, whether or not 
solvent exposed residues on the gp41 C-peptide helix are amenable to mutation is no longer in 
question. What remained in question, however, was what affect these mutations had on the larger 
protein structure. We began to answer this question by comparing protein expression levels of 
mutants to our starting protein (Cpep-ELMO). In addition to selecting for improved target 
affinity, display-based methods often select for proteins with improved protein stability and 
expression
6
. We expressed five of the tightest binding Cpep-ELMO mutants in E. coli as N-
terminal His6 fusions, and purified them by nickel-NTA chromatography. Levels of purified 
eluted proteins were then measured as mg/L with spectroscopy (nanodrop analysis). As shown in 
Figure 4.2C, all but one of our evolved proteins express at higher levels, compared to Cpep-
ELMO. While Cpep-ELMO expresses modestly in E. coli (~2.5 mg/mL), our best performing 
mutants, Cpep3-ELMO and Cpep4-ELMO, express more than twice as well. 
In addition to expressing better in E. coli, evolved mutants retain structural features 
associated with our starting protein (Figure 4.2D) as assed by circular dichroism (CD). This 
makes sense: high efficiency yeast display requires proper protein folding and shuttling to the 
cell surface. Our yeast display screen concomitantly selects for robust expression, protein 
stability, and high affinity for gp41 N-peptide. 
Having established that mutations selected for in our yeast display experiment do not 
appreciably alter protein structure, we next evaluated the effect yeast display evolution had on 
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protein stability. Relative stabilities of Cpep-ELMO, and evolved mutants were measured by 
thermally denaturing (0 °C – 90 °C) each protein and measuring helicity by CD at 222 nm 
(Figure 4.2E). Mutated proteins unfolded within the range 44-57°C, which is not dramatically 
lower than what is the observed melting temperature for Cpep-ELMO (57 °C). Collectively, 
these findings show that proteins evolved in our yeast display screen not only retained affinity 
for gp41 5-helix, but these proteins express—sometimes more robustly—as soluble proteins in E. 
coli, and these proteins retain their structure and stability.  
 
Figure 4.2. (A) ELISA data showing binding between immobilized gp41 5-helix and Cpep-ELMO, or 
mutants described in this work. Error bars represent the standard error of the mean from three 
replicate experiments. (B) Sequence of Cpep-ELMO, and mutants selected for by yeast display in this 
work (Cpep1-ELMO – Cpep11-ELMO). (C) Expression levels, in E. coli, for our starting helix-grafted 
display protein (Cpep-ELMO) and mutants generated from our yeast display screen (Cpep1-11-
ELMO). (D) Circular dichroism spectra for Cpep-ELISA and mutants described in this work. (E) 
Melting data for Cpep-ELMO and mutants described in this work 





























































position 1 2 3 4 5
Cpep-ELMO W W I Y I
Cpep1-ELMO W W V V I
Cpep3-ELMO W W V Y L
Cpep4-ELMO W W I T V
Cpep5-ELMO W W V L V
Cpep8-ELMO W W L Y L
















4.5 Evolved Cpep-ELMO Mutants Suppress HIV Infection in a Live Virus Assay 
Having demonstrated that some of our evolved C-peptide ELMO helix-grafted display 
proteins express better than Cpep-ELMO, retain helical structure, and bind to gp41 5-helix in 
vitro, we next measured their ability to suppress HIV infection using a live virus assay we have 
previously reported
2, 7
. In this method, HIV IIIB is administered to CD4+ mammalian cells 
stably integrated with a plasmid that encodes the HIV-1 long-terminal repeat (LTR) upstream of 
green fluorescent protein. Since HIV-1 Tat/TAR-dependent transcription ultimately leads to the 
expression of GFP, we will be able to see if HIV-1 infects these cells. The number of cells that 
express GFP correlates to the number of cells infected with the virus and can thus be measured 
via flow cytometry. As seen in Figure 4.3, all but one (Cpep8-ELMO) of the evolved helix-
grafted display proteins inhibit HIV-1 entry better than the original helix-grafted display protein, 
Cpep-ELMO. A number of our mutated proteins have dramatically improved Inhibitory 
Constant-50 (IC50) values for inhibition of HIV-1 entry (IC50: Cpep1-ELMO: 0.43
 
µM; Cpep3-
ELMO: 0.31 µM; Cpep4-ELMO: 0.77 µM; Cpep5-ELMO: 0.19 µM. In contrast, the IC50 of our 
starting protein, Cpep-ELMO, was not reached over the course of the concentrations used in this 
experiment. 

























Figure 4.3. Suppression of HIV-1 entry in CD4-positive cells in a live virus assay by Cpep-ELMO, and 





Many disease-relevant protein-protein interactions (PPIs) utilize interfaces that involve an α-
helix and helix-binding groove. In order to disrupt these PPIs, researchers have developed 
various techniques to stabilize helical display of side chains within a peptide or peptide mimetic. 
While these techniques, such as peptide ‘stapling’, ‘hydrogen-bond surrogate’ engineering, and 
helical ‘foldamers’ represent important sectors of biomimetic research, and are important 
reagents for inhibiting disease-relevant PPI’s that feature a helix-binding groove, their synthesis 
and purification can be expensive and laborious. Researchers have also described ‘minimal 
proteins’ with an evolved helix (for tailored recognition); however, these polypeptides do not 
express as a folded protein in E. coli, and must be prepared by solid-phase peptide synthesis, 
which is also laborious and expensive. 
Recently we reported ‘helix-grafted display’, a potentially general solution for displaying a 
folded therapeutically-relevant helix on a protein scaffold. In recently reported work, we showed 
that a Pleckstrin Homology (PH) domain can be resourced as a helix-grafted display scaffold, 
wherein a solvent-exposed helix serves in the wild-type protein serves as a generic canvas upon 
which to paint, or extend, any desired helical interface. To date, our research has focused on the 
development of new proteins that display HIV-1 gp41 C-peptide, an established therapeutic 
reagent. Previously, we showed that Cpep-ELMO, an engineered protein that displays gp41 C-
peptide as a fusion to the N-terminal helix of the ELMO PH domain, binds to gp41 5-helix, 
which mimics the pre-fusogenic state of gp41 and serves as a therapeutically-relevant target. 
Cpep-ELMO potently binds to gp41 5-helix (KD ~ 90 nM) and suppresses HIV entry into CD4-
positive cells, in a concentration-dependent manner. 
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In this work, we sought to optimize properties of Cpep-ELMO mutants by mutating five C-
peptide binding face residues to all possible proteinogenic amino acids, and selecting for 
efficient display on yeast (which relates to stability) and 5-helix recognition. As a result of this 
screen, we reasoned that we could not only improve recognition, but also assess the variability of 
sequences within the solvent-exposed binding face of C-peptide in our helix-grafted protein. 
After screening a ~3.2 million-member Cpep-ELMO derived library, we found that two 
neighboring tryptophan residues (labeled W1 and W2 in this work, Figure 4.1a) are enriched 
for, supporting previous findings detailing their importance in gp41 5-helix recognition. Thus, 
their enrichment demonstrated the ability of our yeast display screen to enrich for residues 
necessary for 5-helix recognition. Other residues, however, (labeled I3, Y4, and I5 in this work, 
Figure 4.1a) exhibit sequence variability. While hydrophobic residues are generally selected for 
at these positions, no single residue emerged as absolutely necessary, or even particularly 
favored. Using eleven proteins (Cpep1-ELMO–Cpep11-ELMO) enriched in our screen, we 
measured their expression in E. coli, structure, and stability. We also measured the ability of 
these proteins to recognize gp41 5-helix, and suppress HIV entry using a live virus assay. These 
characteristics and activities were compared to our starting protein, Cpep-ELMO.  
Satisfyingly, 5 of the 11 favor comparably to Cpep-ELMO when it comes to 5-helix 
recognition; all 5 of these proteins exhibit CD spectra that indicates retention of helical structure; 
all express as soluble proteins in E. coli, and in some cases, expression levels are improved, in 
comparison to the starting protein. Finally, 4 of our evolved proteins (Cpep1-ELMO; Cpep3-
ELMO; Cpep4-ELMO; Cpep5-ELMO) suppress HIV-1 entry better than our starting helix-
grafted protein (Cpep-ELMO). This work shows that solvent exposed residues on C-peptide are 
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amendable to mutation, and that their mutation can generate new proteins with improved 
properties and therapeutic activity. 
 
4.7 Methods 
Protein Expression and Purification Genes were cloned into pET using restriction enzymes 
BamHI and KpnI, downstream of a His6 tag and transformed into BL21s (DE3). Cells were 
grown in 1 L 2XYT cultures containing 100 µg/mL carbenicillin at 37 °C to OD600 =0.5 - 0.8 and 
induced with 1 mM IPTG at 25 °C overnight. Cells were then collected by centrifugation, 
resuspended in PBS buffer (20 mM Na2HPO4 pH 7.4, 100 mM NaCl) and stored at -20 °C. 
Frozen pellets were thawed and sonicated with 1 second pulses for 3 minutes. The lysate was 
cleared by centrifugation (8,000 rpm 10 min.) and the supernatant was mixed with 1 mL of Ni-
NTA agarose resin for 30 min at 4 °C. The resin was collected by centrifugation (4300 rpm, 10 
min.). The resin was sequentially washed with 30 mL of PBS buffer containing 20 mM 
imidazole, 50 mL buffer containing 50 mM imidazole, and 15 mL buffer containing 75 mM 
imidazole. The protein was then eluted with 4 mL PBS buffer containing 400 mM imidazole. 
The proteins were dialyzed against PBS buffer and analyzed for purity by SDS-PAGE. Purified 
protein concentrations were quantified using Beer’s Law at an absorbance of 280 nm, following 
standard practice. 
 
Protein expression was calculated as a measure of eluted protein yield in 
milligrams per liter of induced E. coli culture. 
 
Resolublization of 5-helix Inclusion Bodies 5-helix-His6 was cloned into a modified pETDuet-
1 vector using restriction enzymes NdeI and KpnI and transformed into BL21s (DE3). Cells were 
induced to express 5-helix-His and lysed as described above. The lysate was cleared by 
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centrifugation (8,000 rpm, 20 min.) and the supernatant discarded. The pellet was washed twice 
with PBS buffer containing 0.5 % Triton® X-100 and once with PBS buffer. The pellet was 
resuspended in urea buffer (PBS buffer with 8 M urea and 10 mM imidazole) to resolubilize the 
inclusion bodies and cleared by centrifugation (8,000 rpm, 30 min.) The supernatant was mixed 
with 1 mL of Ni-NTA agarose resin for 1 hour at 4 °C. The resin was collected by centrifugation 
(4,300 rpm, 4 min.). The resin was washed with 50 mL of urea buffer and eluted with 40 mL of 
urea elution buffer (PBS buffer with 6 M urea and 100 mM imidazole) into 460 mL PBS buffer 
by gravity elution while stirring to refold the protein. The 500 mL elution was run through a 
column containing 1 mL of Ni-NTA agarose resin and eluted with 5 mL PBS buffer containing 
400 mM imidazole. The protein was dialyzed against PBS buffer and analyzed for purity by 
SDS-PAGE. Refolding analysis was conducted using CD. Purified proteins were quantified 
using Beer’s Law at an absorbance of 280 nm. Protein expression was calculated as a measure of 
eluted protein yield in milligrams per liter of induced E. coli culture.  
 
Circular Dichroism Proteins were purified as described above. Separately, each protein was 
diluted to 3-10 µM in PBS buffer. Wavelength data are the average of three scans from 250 nm 
to 200 nm in 1 nm steps at 25 °C. Thermal denaturation experiments at 222 nm were run from 0 
to 90 °C in two-degree steps at a two-degree/minute rate of increase with one-minute 
equilibration and data averaging at each temperature. Tm values were obtained from minima of 
the first derivative of θ versus 1/T plots.  
 
Biotinylation 5-helix-His was cloned into a pET vector containing an upstream Avitag™ 
(GLNDIFEAQKIEWHE)-GGSGGSGGT linker using restriction enzymes KpnI and PacI. The 
	 63	
protein was resolublized from inclusion bodies as described above in PBS buffer. His-BirA was 
cloned into pET using restriction enzymes NcoI and KpnI and purified as described above in 
Phosphate buffer. 300 mL of Avitagged™ 5-Helix-His6 protein at 38 µM was incubated with 6 
mL of His6-BirA at 1 mg/mL using Avidity® BirA biotin-protein ligase standard reaction kit at 
30°C for 40 min. Biotinylation was confirmed by Agilent 6220 TOF LC-MS.  
 
In vitro ELISA Helix-grafted Cpep-ELMO proteins were cloned into a pET vector upstream of a 
C-terminal His-GS-FLAG tag (DYKDDDDK) using restriction enzymes NheI and BamHI. 
Proteins were purified as described above in PBS buffer. The biotinylated Avitagged
TM
 5-helix-
His6 (biotin-5helix) was prepared as described above in PBS buffer and diluted to 10 µg/mL. 
Pierce® Streptavidin coated clear 96-well plates with a binding capacity of 5 pmol were pre-
blocked with 200 mL of wash buffer (PBS buffer, 0.5 mg/mL BSA, 0.1% tween® 20) for 1 hour. 
Biotin-5helix was immobilized on the streptavidin-coated plates by incubating 100 µL of diluted 
protein for 1 hour at room temperature, followed by 4x 200 µL washes (5 min). 100 µL of Cpep-
ELMO proteins were incubated at a concentration of 75 nM for 1 hour, followed by 4x 200 µL 
4°C washes (5 min). 100 µL of a 1:10,000 dilution of HRP-conjugated mouse anti-DDDDK 
antibody in Odyssey® Blocking Buffer was incubated for 1 hour at room temperature, followed 
by 4x 200 µL 4°C washes (5 min). Color was developed using TMB-One substrate and 
absorbance was measured at 655 nm on a SynergyMx Microplate Reader. 
 
Infectivity Assay All proteins were shipped on ice in a 20% glycerol-PBS stock. HEK293T cells 
were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 0.5% 
penicillin/streptomycin (P/S). CEM-GFP cells were cultured in RPMI with 10% FBS and 0.5% 
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P/S. The procedure was virtually identical to a previously published variant. The HIV-1 IIIB 
C200 proviral expression construct has been described previously. Viruses were produced by 
transfection of 3.0 µg of Vif-proficient proviral expression construct into 293T cells (3.0x10
6
) 
using TransIT®-LT1 reagent. 48 hr later, virus-containing supernatants were filtered by 0.45 µm 
filters and used to infect into 2.5x10
4
 CEM-GFP cells with varying concentration of inhibitors. 
Infectivity (GFP
+
 cells) was measured by flow cytometry at 2 days post-infection. 
 
Protein Library Preparation EBY100 yeast (trp-, leu-, with the Aga1p gene stably integrated) 
and the pCTCON2 plasmid were generously provided by the Wittrup lab (MIT). The gene 
encoding Cpep-ELMO was amplified by PCR and cloned into pCTCON2 in-frame with Aga2, 
an N-terminal HA-tag, and a C-terminal myc tag, using the restriction enzymes NheI and 
BamHI. When analyzed for display only, Cpep-ELMO displayed efficiently on EBY100 cells 
(~60-85 %, data not shown). Next, the Cpep-ELMO library was created by amplifying the Cpep-
ELMO gene with 5 sites in the N-terminal α-helical region (Trp1, Trp4, Ile8, Tyr11, and Ile15) 
substituted with NNK codons. Using restriction enzymes NheI and BamHI, the library amplicon 
was digested and inserted into a digested pCTCON2 plasmid previously containing an insert 
with several successive stop codons to prevent false positive screening (nonsense pCTCON2). 
The resulting DNA plasmid was used as a template for a second PCR with homologous 
recombination primers, Fwd: (5′-CTC TGG TGG AGG GCG TAG CGG AGG CGG AGG GTC 
GGC TAG C-3′) and Rev: (5′-CGA GCT ATT ACA AGT CCT CTT CAG AAA TCA GCT 
TTT GTT CGG ATC C-3′), which are designed to create an insert with ~40 base pairs of overlap 
with the pCTCON2 vector. The resulting amplicon, containing the randomized sequences, was 
then cloned into pCTcon2 using homologous recombination in EBY100 yeast. Approximately 1 
	 65	
µg of nonsense pCTCON2 vector cut with BamHI and NheI was mixed with ~3 µg of the 
amplified library, ethanol precipitated, and transformed via electroporation into 50 µL of 
electrocompetent EBY100 using 2 mm cuvettes. 10 of these electroporations were performed 
and each was immediately rescued with 2 mL pre-warmed YPD and combined for 2 hours at 30 
°C. After rescue, yeast were centrifuged at 2,500 xg for 1 minute, and supernatant YPD was 
removed. Yeast were resuspended in 1 mL fresh SD-CAA (5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4 
• H2O, 20 g/L dextrose, 6.7 g/L yeast nitrogen base lacking amino acids, 5 g/L casamino acids, 
200 kU/L penicillin, 0.1 g/L streptomycin). A small portion was plated by serial dilution onto 
SD-CAA plates, and incubated at 30 °C for 3 days in order to determine the transformation 
efficiency. The remainder were cultured in 50 mL SD-CAA for yeast display screening. 
Efficiency of homologous recombination transformation was determined to be 1 x 10
7





Yeast Display Screening After 2-3 days of growth in SD-CAA, the library was sub-cultured in 
SD-CAA at an initial density of 0.5 x 10
7
 cells/mL and grown to a density of 2.0 x 10
7
 cells/mL. 
Yeast were subsequently sub-cultured in SG-CAA (Galactose containing induction media) to a 
concentration of 1.0 x 10
7
 cells/mL and grown for 1-2 days shaking at 250 RPM at a temperature 
of 25 °C. For each round of screening, approximately 10
8
 cells were pelleted and washed with 1 
mL of 4 °C PBS-BSA (Corning CellGro PBS 1x with 1 g/L BSA filter sterilized). Yeast were 
subsequently incubated with biotin-5helix at the concentrations given in the table below and a 
1:250 dilution of FITC-conjugated anti-myc antibody at room temperature. After incubation, the 
yeast cells were incubated on ice for 5 minutes, pelleted at 12,000 xg for 30 seconds 4 °C and 
washed with 1 mL ice-cold PBS-BSA. The yeast was pelleted again and incubated with a 1:100 
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dilution of SAPE in PBS-BSA on ice for 1 hour. After incubation, a final wash with ice-cold 
PBS-BSA was performed, and yeast positive for both FITC (display) and R-Phycoerythrin (5-
helix-binding) were sorted into 7 mL of SD-CAA media using a MoFlo Flow Cytometer 
(Beckman-Coulter). Sorted yeast were transferred to 50 mL of pre-warmed SD-CAA and 
incubated at 30 °C for 3 days shaking at 250 RPM. Additionally, plasmid DNA was recovered 
from the sorted library using a Zymoprep yeast plasmid miniprep II kit. This DNA was used to 
transform Invitrogen, Top10 E. coli.  
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In this work, I designed the helix grafting strategies, as well as carried out molecular 
cloning and protein purifications. I also performed all circular dichroism, cell lysate ELISAs and 
co-purification experiments. Susanne Walker, a fellow graduate student, constructed the design 
and screening of the protein library. Terumasa Ikeda, our post-doctoral collaborator at the 
University of Minnesota, performed all live HIV-1 infectivity assays. 
 
5.2 Introduction 
Previous studies suggested a relationship between the size of the helix-grafted display 
scaffold and HIV-1 entry inhibition: smaller scaffolds are more effective.
1
 We therefore set our 
sights on a miniature (<10 kDa) PH domain (or structurally related protein) that expresses well in 
E. coli and is amenable to the extensive helix mutagenesis required for grafting and sequence 
optimization. Analysis of the Protein Data Bank (PDB), and literature, revealed Sac7d – a 7 kDa 




	This chapter was adapted from: 
Tennyson, R. L.;  Walker, S. N.;  Ikeda, T.;  Harris, R. S.; McNaughton, B. R., Evolved Proteins 
Inhibit Entry of Enfuviritde-Resistant HIV-1. ACS Infect. Dis Just Accepted.	
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Sac7d was engineered, using helix-grafted display, to function as a C-peptide mimic, and 
the resulting protein (Sac7d-Cpep) was analyzed for structural and functional fidelity. Sac7d-
Cpep (Figure 5.1A) expresses as a soluble protein in E. coli, and circular dichroism experiments 
show that it maintains structural features found in the wild-type protein (Figures 5.1B and 
S5.1A). When 5-helix-His6 is expressed in E. coli in the absence of a binding partner, it 
expressed in the form of an inclusion body, that must be refolded. This is likely due to 
aggregation caused by the solvent-exposed hydrophobic C-peptide binding site. However, when 
5-helix-His6 is appropriately bound by another protein (lacking a His6 tag), effectively filling the 
hydrophobic C-peptide binding site, both proteins can be co-purified from E. coli lysate with 












































































Figure 5.1 (A) Helix-grafted Sac7d-Cpep. Blue represents grafted C-peptide residues. Gray represents 
Sac7d-residues. (B) Circular dichroism data for Sac7d and Sac7d-Cpep. (C) Sac7d-Cpep binds 5-helix 
in E. coli. Lane 1: E. coli cell lysate containing Sac7d and 5-helix-His6. Sac7d does not co-purify with 5-
helix-His6 on nickel-NTA agarose. Lane 2: E. coli cell lysate with Sac7d-Cpep and 5-helix-His6. Sac7d-
Cpep co-purifies with 5-helix-His6 on nickel-NTA agarose. (D) Sac7d-Cpep potently inhibits HIV entry in 
a live virus assay (IC50 1.9-12.4 nM). Error bars represent the standard error of the mean (SEM) for three 
separate experiments. If error bars are not visible, error is smaller than the data point. 
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observe no purified protein following incubation with nickel-NTA agarose beads and elution 
with imidazole (Figure 5.1C, lane 1), indicating that Sac7d does not appreciably bind 5-helix-
His6. However, when 5-helix-His is expressed concomitantly with Sac7d-Cpep, both proteins 
readily co-purify following incubation with nickel-NTA agarose beads and elution with 
imidazole (Figure 5.1C, lane 2), indicating that the two proteins form a tight association in a 
complex biological solution that contains thousands of alternative proteins, and a virtual sea of 
nucleic acids and other biological molecules. Formation of the desired complex was further 
assessed by ELISA, which indicates binding between Sac7d-Cpep and immobilized 5-helix, but 
no appreciable affinity between Sac7d and 5-helix (Figure S5.1B).  
 
5.3 Sac7d-Cpep Potently Inhibits HIV Entry in a Live Virus Assay 
 To measure inhibition of HIV entry, or lack thereof, we previously used a live-virus assay 
that links HIV infection of CD4-positive T cells to GFP fluorescence.
3, 4
 In this method, HIV 
IIIB is administered to CD4+ T cells stably integrated with a plasmid that encodes the HIV-1 
long-terminal repeat (LTR) upstream of green fluorescent protein (GFP).
5
 Since HIV Tat/TAR-
dependent transcription ultimately leads to the expression of GFP, cells that express GFP 
correlates to the number of infected cells and can thus be measured via flow cytometry. Sac7d 
does not inhibit HIV entry (data not shown). In contrast, Sac7d-Cpep potently inhibits HIV entry 
(IC50 1.9-12.4 nM, Figure 5.1D; Table 5.1, entry 1), and compares similarly to Enfuvirtide (IC50 
0.7-3.5 nM over 6 different experiments over the course of this study, each performed in 
triplicate, Figure 5.1D; Table 5.1, entry 2) and gp41 C-peptide (IC50 1.0-6.7 nM, Figure 5.1D; 
Table 5.1, entry 3). In addition to Sac7d-Cpep, we prepared and evaluated a number of other 
helix-grafted proteins, in which the helix consists of the Enfuvirtide sequence, or C-46, which 
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contains C-peptide and Enfuvirtide sequences (Figure S1C and Table S5.2). While these 
proteins express as soluble proteins from E. coli, they are less active as HIV entry inhibitors 
(Sac7d-C46 IC50 23.6 nM and Sac7d-Enfuvirtide 39.7 nM). Moreover, since Enfuvirtide lacks 
tryptophan residues necessary for 5-helix recognition, this scaffold cannot be evolved for 
improved 5-helix recognition. Given these results, we focused on Sac7d-Cpep as a starting point 
to generate peptides with improved therapeutic properties including affinity, solubility, and 
durability. 
 
5.4 First-Generation Helix Evolution Provides Potent Entry Inhibitors with Dramatically 
Improved Expression in E. coli 
 We set out to use protein evolution to identify a diverse set of Sac7d-Cpep based proteins 
with affinity for 5-helix. We envisaged that if evolved forms of Sac7d-Cpep—with sequence 
diverse residues on the solvent-exposed helix face—retain affinity 5-helix, the molecular 
underpinnings of recognition could vary substantially. If true, we reasoned that it would likely be 
more difficult for HIV to rapidly evolve resistance to the polyclonal nature of an ensemble 
consisting of mixed proteins, compared to a single molecule like Enfuvirtide. Moreover, we 
reasoned that evolved proteins could bind viral gp41 in a manner that overcomes mutations 
leading to Enfuvirtide resistance.  
The first two C-peptide grafted residues on Sac7d-Cpep are both tryptophans (WW, 
white spheres, Figure 5.2A). In the context of helix-grafted proteins, we have demonstrated 
these residues are necessary for recognition of 5-helix. 
3
 Thus, we avoided mutating these 
tryptophans in our library. In the first-generation of helix optimization, we mutated five residues 
(grafted and native) on the solvent-exposed face of the helix (EIYTI, light blue spheres, Figure 
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5.2A) to all 20 proteinogenic amino acids, generating a protein library of approximately 3.2 x 
10
6
. Yeast were induced to display the Sac7d-Cpep based library, equipped with an N-terminal 
Myc tag. As in our prior work, yeast were concomitantly incubated with a FITC-labeled anti-
Myc antibody and biotinylated gp41 5-helix. Following a brief washing step, streptavidin-






Figure 5.2 (A) Helix optimization strategy. Light blue residues were optimized in generation 1; tan 
residues were optimized in generation 2. (B) Yeast display optimization assay. (C) Representative 
yeast display data from generation 1 screening. (D) Sequence logo for residues optimized during 
generation 1 of yeast display screening. (E) Inhibition of HIV entry of Sac7d-Cpep, C-peptide, 
Enfuvirtude, and generation 1 optimized proteins. Error bars represent the standard error of the mean 
(SEM) for three separate experiments. If error bars are not visible, error is smaller than the data 
point. 
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surface, by virtue of a surface protein/5-helix interaction, will be bound by SAV-PE (Figure 
5.2B). Following additional washing, yeast were analyzed by flow cytometry, and sorted for the 
highest FITC fluorescence intensity (display efficiency) and PE red pigment intensity (5-helix 
binding efficiency). Yeast displaying tightest affinity proteins were enriched over the course of 
two rounds of screening against 1 nM or 100 pM biotinylated 5-helix, respectively. In both 
rounds, 10 nM Cpep-ELMO was added as a competitor for 5-helix recognition (Figure S5.2A 
and Table S5.1). A representative flow cytometry experiment (1 nM 5-helix incubation with 10 
nM Cpep-ELMO competitor) is shown in Figure 3C. 
 After two rounds of first-generation optimization we sequenced 30 clones, revealing 14 
unique sequences. The amino acid preference for each randomized position is depicted in Figure 
3D. For the first randomized residue (glutamic acid, E, Figure 5.2A), we observe a preference 
for the wild-type amino acid. Aspartic acid was also observed in selected proteins, suggesting 
that a carboxylic acid containing side chain is favored at this position. However, significant 
heterogeneity was observed at the four other residues optimized by yeast display – indicating that 
multiple solutions to potent recognition of 5-helix exist. While the overwhelming majority of the 
amino acids we enriched for are hydrophobic, the steric footprint of these residues varies 
dramatically. New 5-helix binders were first evaluated by ELISA (Figure S5.2B) and seven 
proteins were identified as competitive with Sac7d-Cpep (greater than 90% ELISA signal was 
generated, relative to Sac7d-Cpep). These proteins were next evaluated for their ability to inhibit 
HIV entry. Satisfyingly, all seven proteins inhibit HIV entry virtually identically (Figure 5.2E, 
Table 5.1, entry 4-10). To differentiate between these proteins, we compared their expression 
yield in E. coli (Figure S5.2C). We observed a 18-fold increase in expression of Sac7d-Cpep1.1, 
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compared to Sac7d-Cpep. Residues optimized in Sac7d-Cpep1.1 are EAWLL, compared to wild-
type residues EIYTI; this protein was used as a starting point for second-generation evolution. 
 
5.5 Second-Generation Helix Evolution Delivers a Library of Potent Entry Inhibitors 
 Solvent-exposed residues on the C-terminal region of the grafted helix of Sac7d-Cpep1.1 
(LISQQ, tan spheres, Figure 5.2A) were randomized and enriched for 5-helix recognition by 
yeast display. As before, these five residues were randomized, generating a 3.2 x 10
6
 protein 
library and highest affinity binders to 5-helix were enriched by flow cytometry. Second-
generation helix optimization was conducted over the course of three rounds (4 nM; 200 pM, or 
50 pM biotinylated 5-helix with 1 nM Sac7d-Cpep as competitor, Figure S5.3A and Table 
S5.1).  
Following the final enrichment round, we sequenced 50 plasmids that encode for 20 
unique protein sequences. We observed significant sequence variability (Figure 5.3A), 
suggesting that multiple solutions to potent 5-helix recognition exist within this region of the C-
Table 5.1 Sequence of HIV entry inhibitors, and associated half maximal inhibitory constant (IC50) values 
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peptide helix. Affinity for 5-helix recognition was again assessed by ELISA (Figure S5.3B) and 
lowest affinity binders were triaged. Evolved proteins with low expression in E. coli were also 
eliminated (Figure S5.3C). Entry inhibition was measured for seven second-generation proteins 
(Figure 5.3B). Despite substantial differences in their sequences, all evaluated proteins potently 
inhibit HIV entry (IC50 4.1-29.0 nM, Table 1, entry 11-17). Moreover, despite dramatic 
resurfacing of the solvent-exposed face of C-peptide, proteins evolved in second-generation helix 
optimization expressed 2-9-fold more efficiently in E. coli, compared to Sac7d-Cpep (Figure 
S5.3C). 
 
5.6 Evolved Proteins Bind Enfuvirtide-Resistant 5-helix and Inhibit Entry of Enfuvirtide-
Resistant HIV 
 Given the sequence diversity of the evolved helix, we reasoned that at least some of the 
evolved proteins might recognize 5-helix (and thus gp41) in slightly different ways, and/or with 
a.








































































































































A B C D 
Figure 5.3. (A) Sequence logo for residues optimized during generation 2 of yeast display screening 
(B) Inhibition of HIV entry of Sac7d-Cpep, C-peptide, Enfuvirtide, and generation 2 optimized 
proteins. Error bars represent the standard error of the mean (SEM) for three separate experiments. If 
error bars are not visible, error is smaller than the data point. (C) Position of V38A and N42D 
mutations within the N-heptad repeat (brown) of gp41. Mutations are highlighted in red. C-peptide is 
highlighted in blue; regions evolved generationally are shown. (D) Inhibition of V38A/N42D HIV entry. 
Error bars represent the standard error of the mean (SEM) for three separate experiments. If error 




different contributions to the binding energy at each evolved position. Given this, we rationalized  
that some of these evolved proteins could, in principle, inhibit the entry of a mutant form of gp41 
that endows resistance to Enfuvirtide. 
 Enfuvirtide is given to patients as a last resort therapy due to, at least in part, rapid 
generation of resistance due to mutation of gp41. In patient-derived studies, a frequent gp41 
mutation within the N-terminal heptad repeat (NHR, Figure 5.3C, brown) region that endows 
Enfuvirtide resistance is V38A (Figure S5.4A). Additionally, double mutations within the same 
region (V38A/N42D; Figure 5.3C) have been found to confer cross-resistance to Enfuvirtide 
and C-peptide.
6
 To determine if our evolved proteins are functional against these clinically 
relevant forms of HIV, we generated Enfuvirtide-resistant HIV IIIB virions with the V38A single 
substitution or V38A/N42D double mutation. As in the live virus assay with the wild-type virus, 
HIV IIIB V38A or HIV IIIB V38A/N42D infection of CD4-positive T cells is linked to GFP 
fluorescence and can be quantified using flow cytometry. 
All eight of the evolved proteins we tested potently inhibited entry of the Enfuvirtide-resistant 
double mutant strain (IC50 4.3-83.7 nM), and compared favorably to C-peptide (IC50 72.9 nM; 
Figure 5.3D, and Table S5.2). A similar trend was seen for the single mutant strain (Figure S5.4 
and Table S5.2). Interestingly, Sac7d-Cpep and Sac7d-Cpep1.1 also inhibited the entry of both 
single and double mutant forms of HIV (Figure 5.3D and Table 5.1). This is potentially due to a 
number of factors, including stabilization and/or slight alteration of the helix, to the extent that 





5.7 Fusions Designed for Serum Stability Potently Inhibit HIV Entry 
 Small proteins like Sac7d-Cpep, and evolved forms thereof, are typically cleared rapidly. 
This contrasts to antibodies, which have much longer lifetimes in vivo (e.g., IgG half-life is 
approximately 20 days). Antibody stability is the result of an interaction between the neonatal 
receptor (FcRn) on the surface of epithelial cells, and an epitope largely within the CH3 domain 
of a single chain of the fragment crystallizable region (Fc).
7-10
 This single chain is referred to as 
monomeric Fc (mFc, Figure 5.4A)
11, 12
; a single CH3 domain is referred to as monomeric CH3 
(mCH3, Figure 5.4A).
13
 Binding between mFc and FcRn is pH-dependent. Formation of the 



































































































Figure 5.4 (A) IgG, with mFc highlighted in blue. mFc consists of mCH2 and mCH3. Fusions either 
contain complete mFc or the mCH3 domain. (B) HIV entry inhibition with mCH3-Sac7d-Cpep, compared 
to Sac7d-Cpep, Enfuvirtide, and C-peptide. (C) HIV entry inhibition with mFc-Sac7d-Cpep, compared to 
Sac7d-Cpep, Enfuvirtide, and C-peptide. (D) HIV entry inhibition with SAbp-Sac7d-Cpep, compared to 
Sac7d-Cpep, Enfuvirtide, and C-peptide. Error bars represent SEM for three separate experiments. If 
error bars are not visible, error is smaller. 
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circulatory system to the cell interior. Once inside an endosome, which has a lower pH compared 
to the cytosol, the complex dissociates and the antibody is shipped back to the circulatory 
system. This biological shell game allows antibodies to evade degradation by proteases. 
Researchers have shown that fusion of a protein to mFc, or mCH3 can dramatically improve in 
vivo stability, and mFc or mCH3 fusions can often be expressed in E. coli. 
On the basis of these earlier reports, we prepared two fusions, mFc-Sac7d-Cpep and mCH3-
Sac7d-Cpep, and measured their ability to inhibit HIV entry. Since the version of Sac7d we 
began with binds IgG, all protein fusions contain a reversion L33T mutation that diminishes 
affinity for IgG. ELISA experiments indicate no appreciable binding between mFc and mCH3 
(Figure S5.5A). Consistent with a relationship between protein size and entry inhibition potency, 
mFc-Sac7d-Cpep (37 kDa) inhibits HIV entry (IC50 282.9 nM, Figure 5.4B; Table 5.1, entry 
18), but is approximately 23-fold less potent than Sac7d-Cpep. mCH3-Sac7d-Cpep (24 kDa) 
inhibits HIV entry, but the increased size results in 1.5-fold decreased potency (IC50 18.0 nM) 
compared to Sac7d-Cpep (Figure 5.4C; Table 1, entry 19). Additionally, mCH3-Sac7d-Cpep 
and mFc-Sac7d-Cpep proteins containing a (GGS)3 linker between the mFc or mCH3 and Sac7d-
Cpep performed similarly to proteins without a linker, despite modest increase in size (Figure 
S5.5B-C and Table S5.2). 
 Fusion to a polypeptide that binds serum albumin has also been reported as a strategy to 
improve in vivo stability of biologics.
14
 We prepared a fusion consisting of a 20-amino acid 
serum albumin binding peptide (SAbp) to Sac7d-Cpep (SAbp-Sac7d-Cpep). SAbp-Sac7d-Cpep 
potently inhibits HIV entry (IC50 3.9 nM; Figure 5D; Table 5.1, entry 20). We also created a 
SAbp fusion to the C-terminus of Sac7d-Cpep. To physically separate the two domains, as well 




 between Sac7d-Cpep and SAbp. This fusion protein (Sac7d-Cpep-hfl-
SAbp) showed similar HIV entry inhibition (IC50 9.7 nM, Figure S6D). 
 
5.8 Conclusion 
 Here, we report a new, minimalist, helix-grafted display protein (Sac7d-Cpep), that 
potently inhibits HIV entry in a live virus assay (IC50 1.9-12.4 nM). Yeast display evolution  of 
both grafted and native residues on the solvent-exposed face of the helix led to a library of HIV-
1 entry inhibitors with virtually identical potencies, despite significant sequence variation. While 
hydrophobic residues are principally selected for, the size of evolved residue side chains varies 
dramatically. Importantly, evolved biologics potently inhibit the entry of HIV-1 with clinically 
relevant mutations, leading to Enfuvirtide-resistance. Helix-grafted HIV-1 entry inhibitors fused 
to either mCH3, mFc, or SAbp, designed to endow serum stability and extended in vivo 
residence, retain the ability to inhibit HIV-1 entry in a live virus assay; however, we do observe a 
correlation between the size of the fusion and potency of inhibition – larger fusions were less 
potent. Given the amino acid diversity of evolved biologics we report, we speculate that these 
biologics bind the C-peptide binding cleft of 5-helix somewhat differently, with varied energetic 
contributions at each evolved amino acid position. We also speculate that a cocktail of these 
proteins might present a challenge for the emergence of resistance, since it is unlikely that HIV-1 
is able to rapidly evolve resistance against the entire therapeutic cocktail. 
 
5.9 Future Directions 
Since the mechanism of membrane fusion is similar for enveloped viruses, helix-grafted 
display could be applied to their corresponding α-helical proteins to find potent inhibitors. 
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Attaching other viral C- peptides to these PH domains could have varying solubility. 
PLECKSTRIN, HOMER, ELMO, and Sac7d would be excellent potential scaffolds since they 
express well as their wild-type. Alternatively there are many other therapeutically relevant 
protein-protein interactions (PPIs) that involve a helix and a helical binding cleft beyond viral 
membrane fusion Further investigations could show which PH domains are best for their 
corresponding target. ELMO was amendable to mutations on the N and C terminus, which could 
be advantageous given the target. Sac7d’s small size is a large benefit for targeting sterically 
constrained PPIs. Given these strong initial results, the helix-grafted display method shows 
promise as a platform for helix stabilization and other targets should further investigated to show 
the broad utility of this platform. 
 
5.10 Methods 
Protein Expression and Purification Genes were cloned into pET using BamHI and KpnI, 
downstream of a His6 tag and transformed into BL21s (DE3). Cells were grown in 0.5 L LB 
cultures containing 100 µg/mL carbenicillin at 37 °C to OD600 =0.5 - 0.8 and induced with 1 µM 
IPTG at 25 °C overnight. Cells were then collected by centrifugation, resuspended in PBS buffer 
(20 mM Na2HPO4 pH 7.4, 100 mM NaCl) with protease tablets and stored at -20 °C. Frozen 
pellets were thawed and sonicated with 1 sec pulses for 2 min. The lysate was cleared by 
centrifugation (11,899 xg, 10 min.) and the supernatant was mixed with 1 mL of Ni-NTA 
agarose resin for 30 min at 4 °C. The resin was collected by centrifugation (4303 xg, 10 min.). 
The resin was sequentially washed with 30 mL of PBS buffer containing 20 mM imidazole, 50 
mL PBS buffer containing 50 mM imidazole, and 15 mL PBS buffer containing 75 mM 
imidazole. The protein was then eluted with 4 mL PBS buffer containing 400 mM imidazole. 
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The proteins were dialyzed against PBS buffer and analyzed for purity by SDS-PAGE. Protein 
expression was calculated as a measure of eluted protein yield in milligrams per liter of induced 
E. coli culture. Protein fusions with either mFc or mCH3 were grown up in 2XYT and induced at 
20 °C for 15-20 hours for maximal yield.  
 
Circular Dichroism Proteins were purified as described. Separately, each protein was diluted to 
5-12 µM in PBS buffer. Wavelength data are the average of three scans from 250 nm to 200 nm 
in 1 nm steps at 25 °C.  
 
Cell lysate ELISA Sac7d, Sac7d-Cpep, and C-peptide were cloned into MCS1 of pETDuet with 
FLAG tags using NcoI and NotI. The 5-Helix with a C-terminal His6 tag was cloned into MCS2 
of pETDuet using NdeI and KpnI. For protein expression, constructs were transformed into 
BL21 cells (DE3). Cells containing the co-expressed pair were inoculated and induced in 10 mL 
LB cultures overnight. Cells were spun down and resuspended in 10 mL PBS buffer, lysed by 
sonication, and spun down to remove cell debris. Cleared lysates were incubated on clear Ni-
NTA coated plates for 1 hr at room temperature and each well was washed 3x with 200 µL wash 
buffer (PBS Buffer, 0.1% Tween® 20, and 0.01 mg/mL BSA). An HRP-conjugated mouse anti-
FLAG antibody in LiCor Blocking Buffer was incubated for 1 hr at room temperature, followed 
by 3 washes. Color was developed using TMB-One substrate and absorbance was measured at 
655 nm on a SynergyMx Microplate Reader. 
 
Plasmid Construction of HIV-1 infectivity Assays HIV-1 IIIB C200 proviral expression 
construct has been described previously. NheI/BamHI fragments of the env gene encoding 
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substitutions (gp41 V38A or gp41 V38A N42D) were synthesized (INTEGRATED DNA 
TECHNOLOGIES), cloned into pJET1.2/blunt cloning vector (Thermo Scientific) by amplifying 
with the following primer set (5’-GCT AGC AAA TTA AGA GAA CAA TTT GG-3’ and 5’-
GGA TCC GTT CAC TAA TCG AAT GG-3’) and sequenced as described previously. Then, 
DNA fragments were inserted into the proviral DNA expression plasmid at NheI/BamHI site. 
 
Infectivity Assays The procedure of HIV-1 infectivity assays was previously reported. Briefly, 
viruses were produced by transfection of 3.0 µg of HIV-1 IIIB C200 proviral expression 
construct into 293T cells (3.0x10
6
) using TransIT®-LT1 reagent. 48h later, virus-containing 
supernatants were filtered by 0.45 µm filters (Millipore) and used to infect into 2.5x10
4
 CEM-
GFP cells with varying concentration of inhibitors including T-20 and C34. Infectivity 
(GFP
+
 cells) was measured by flow cytometry at 2 days post-infection. 
 
Resolublization of 5-helix Inclusion Bodies 5-helix-His6 was cloned into a modified pETDuet 
vector using NdeI and KpnI and transformed into BL21 cells. Cells were induced to express 5-
helix-His6 and lysed as described above. The lysate was cleared by centrifugation (11,899 x g, 20 
min) and the supernatant was discarded. The pellet was washed twice with PBS buffer 
containing 0.5 % Triton® X-100 and once with PBS buffer, resuspended in urea buffer (PBS 
buffer with 8 M urea and 10 mM imidazole) to resolubilize the inclusion bodies and cleared by 
centrifugation (11,899 xg, 30 min.) The supernatant was mixed with 1 mL of Ni-NTA agarose 
resin for 1 hr at 4 °C. After centrifugation (4,303 x g, 4 min), the resin was washed with 50 mL 
of urea buffer and eluted with 40 mL of urea elution buffer (PBS buffer with 6 M urea and 100 
mM imidazole) into 460 mL PBS buffer by gravity elution while stirring to refold the protein. 
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The 500 mL elution was run through a column containing 1 mL of Ni-NTA agarose resin and 
eluted with 5 mL PBS buffer containing 400 mM imidazole. The protein was dialyzed against 
PBS buffer and analyzed for purity by SDS-PAGE. Refolding analysis was conducted by CD. 
Purified proteins were quantified using Beer’s Law at an absorbance of 280 nm. Protein 
expression was calculated as a measure of eluted protein yield in milligrams per liter of induced 
E. coli culture. 
 
Biotinylation 5-helix-His6 was cloned into a pET vector containing an upstream Avitag™ 
(GLNDIFEAQKIEWHE)-GGSGGSGGT linker using KpnI and PacI. The protein was 
resolubilized from inclusion bodies as described above in PBS. His6-BirA was cloned into pET 
using NcoI and KpnI and purified as described above in PBS. 300 mL of Avitagged™ 5-Helix-
His6 protein at 38 µM was incubated with 6 µL of His6-BirA at 1 mg/mL using Avidity® BirA 
biotin-protein ligase standard reaction kit at 30°C for 40 min. Biotinylation was confirmed by 
Agilent 6220 TOF LC-MS.  
 
In vitro ELISA Sac7d and helix-grafted Sac7d-Cpep were cloned into a pET vector downstream 
of an N-terminal His6-FLAG tag (DYKDDDDK) using BamHI and Kpn1 or BamHI and PacI. 
Proteins were purified as described above in PBS buffer. The biotinylated Avi-tagged 5-helix-
His6 (biotin-5-helix) was prepared as described above in PBS buffer and diluted to 10 µg/mL. 
Pierce® Streptavidin coated clear 96-well plates with a binding capacity of 5 pmol were pre-
blocked with 200 µL of wash buffer (PBS, 0.5 mg/mL BSA, 0.1% tween® 20) for 1 hr. Biotin-5-
helix was immobilized on the streptavidin-coated plates by incubating 100 µL of diluted protein 
for 1 hr at room temperature, followed by 3 washes. 100 µL of Sac7d or Sac7d-Cpep was 
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incubated in various concentrations for 1 hr and washed 3 times at 4°C (All concentrations of 
incubated helix-grafted protein were above ligand-depleting conditions for binding the 5 pmol 
immobilized biotin-5-helix in each well). An HRP-conjugated mouse anti-DDDDK antibody in 
LiCor Blocking Buffer (1:10,000) was incubated for 1 hr at room temperature, followed by 4 
washes at 4°C. Color was developed using TMB-One substrate at room temperature and 
absorbance was measured at 655 nm on a SynergyMx Microplate Reader after 20 min.  
 
Preparation of Protein Library Generation 1 EBY100 yeast (trp-, leu-, with the Aga1p gene 
stably integrated) and the pCTCON2 plasmid were generously provided by the Wittrup lab 
(MIT). The gene encoding Sac7d-Cpep was amplified by PCR and cloned into pCTCON2 in-
frame with Aga2, an N-terminal HA-tag, and an N-terminal myc tag, using the restriction 
enzymes NheI and XhoI. When analyzed for display only, Sac7d-Cpep displayed efficiently on 
EBY100 cells (~60-85 %, data not shown). Next, the Sac7d-Cpep generation 1 library was 
created by amplifying the N-terminal Sac7d-Cpep gene with an N-terminal homologous 
recombination forward primer annealing to 40 base pairs upstream of the gene on pCTCON2 and 
a reverse homologous recombination primer containing 5 sites in the C-terminal α-helical region 
(Glu65, Ile66, Tyr69, Thr70, and Ile73) substituted with NNK codons and annealing to 40 base 
pairs downstream of the final NNK mutation. The resulting amplicon, containing the randomized 
sequences, was then cloned into a nonsense-Cpep pCTcon2 vector containing the remainder of 
the C-terminus of Sac7d-Cpep post-mutations by adding ~1 µg of nonsense-Cpep pCTCON2 
vector cut with NheI and NcoI mixed with ~3 µg of the amplified library, ethanol precipitated, 
and transformed via homologous recombination into electrocompetent EBY100. Eight of these 
electroporations were performed to reach appropriate transformation efficiency. Rescued yeast 
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were resuspended in 1 mL fresh SD-CAA (5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4 • H2O, 20 g/L 
dextrose, 6.7 g/L yeast nitrogen base lacking amino acids, 5 g/L casamino acids, 200 kU/L 
penicillin, 0.1 g/L streptomycin). A small portion was plated by serial dilution onto SD-CAA 
plates, and incubated at 30 °C for 3 days in order to determine the transformation efficiency. The 
remainder were cultured in 50 mL SD-CAA for yeast display screening. Efficiency of 
homologous recombination transformation was determined to be 1.072 x 10
7
 – 2.19 x 10
7
 using 
the equation transformation efficiency = (# colonies x Vol quenched)/(dilution x Vol plated). 
 
Preparation of Protein Library Generation 2 The gene encoding the best performing mutant 
from generation 1, Sac7d-Cpep1.1 was electroporated back into pCTCON2 in-frame with Aga2, 
an N-terminal HA-tag, and an N-terminal myc tag, using NheI and XhoI. When analyzed for 
display only, Sac7d-Cpep1.1 displayed efficiently on EBY100 cells. Next, the Sac7d-Cpep 
generation 2 library was created by amplifying the N-terminal Sac7d-Cpep1.1 gene with an N-
terminal homologous recombination forward primer annealing to 40 base pairs upstream of the 
gene on pCTCON2 and a reverse homologous recombination primer containing 5 sites in the C-
terminal a-helical region (Leu76, Ile77, Ser80, Gln83, and Gln84) substituted with NNK codons 
and annealing to 40 base pairs downstream of the final NNK mutation. The resulting amplicon, 
containing the randomized sequences, was then cloned into a nonsense-Cpep2 pCTCON2 vector 
containing the remainder of the C-terminus of Sac7d-Cpep1.1 post-generation 2 mutations using 
homologous recombination in EBY100 yeast by using approximately 1 µg of nonsense-Cpep2 
pCTCON2 vector cut with NheI and PacI mixed with ~3 µg of the amplified generation 2 
library, ethanol precipitated, and transformed via ten electroporations. Rescued yeast plated as 
described previously to determine the transformation efficiency and the remainder were cultured 
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in 50 mL SD-CAA for yeast display screening. Efficiency of homologous recombination 
transformation was determined to be 2.084 x 10
7




Yeast Display Screening After 2-3 days of growth in SD-CAA, the library was sub-cultured in 
SD-CAA at an initial density of 0.5 x 10
7
 cells/mL and grown to a density of 2.0 x 10
7
 cells/mL. 
Yeast were subsequently sub-cultured in SG-CAA (Galactose containing induction media) to a 
concentration of 1.0 x 10
7
 cells/mL and grown for 1-2 days shaking at 250 rpm at 25 °C. For 
each round of screening, approximately 10
8
 cells were pelleted and washed with 1 mL of 4 °C 
PBS-BSA (PBS buffer with 1 g/L BSA filter sterilized). Yeast were subsequently incubated with 
biotin-5-helix at the concentrations given in Table S2 and a fluorescein isothiocyanate (FITC)-
conjugated anti-myc antibody (1:250) at room temperature. After incubation, the yeast cells were 
incubated on ice for 5 min, pelleted at 12,000 xg for 30 sec 4 °C and washed with 1 mL ice-cold 
PBS-BSA. The yeast were pelleted again and incubated with a 1:100 dilution of streptavidin, R-
Phycoerythrin (SAPE) in PBS-BSA on ice for 1 hr. After incubation, a final wash with ice-cold 
PBS-BSA was performed, and yeast positive for both FITC (display) and R-Phycoerythrin (PE, 
5-helix-binding) were sorted into 7 mL of SD-CAA media using a MoFlo Flow Cytometer 
(Beckman-Coulter). Sorted yeast were transferred to 50 mL of pre-warmed SD-CAA and 
incubated at 30 °C for 3 days shaking at 250 rpm. Additionally, plasmid DNA from the sorted 
library population was recovered using a Zymoprep yeast plasmid miniprep II kit. This DNA 





5.11 Proteins Used in This Work 
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Chapter 2 Supplemental Data 
expected mass (GLUE-Cpep) = 17,069 Da [M+1] 
observed mass = 17,069 Da 
































AKT2 1P6S 20 111 18 Yes Yes 
APPL1 PH 2ELB 18 112 16 Yes No 
APPL1 PTB 2ELA 36 145 25 Yes No 
DOK5 1J0W 21 104 20 Yes No 
DYNAMIN 2DYN 13 105 12 Yes No 
ELMO (C-term) 2VSZ 18 147 12 Yes No 
ELMO (N- term) 2VSZ 27 147 19 Yes No 
GLUE 2CAY 18 128 14 Yeast No 
HOMER 1I2H 26 116 22 Rat No 
PLECKSTRIN 2I5F 17 105 16 Yes No 




Figure S3.1 SDS page gel and coomassie staining of purified proteins. Top gel show purified 
wild-type PH domains and bottom gel shows helix grafted proteins 

















Figure S3.3 Circular dichroism data (222 nm) showing temperature-dependent melting of N 
and C term helix grafted ELMO proteins 
Figure S3.4 % full length helix grafted protein after 12 hour incubation with human serum. 




































Table S4.1: Experimental conditions for yeast display 
 
[biotin-5helix, nM] Yeast Screened Yeast Sorted % positive 
Round 1 500 ~7 x 10
7
 ~2.8 x 10
5
 0.40% 
Round 2 100 ~5 x 10
6















Figure S5.1: Helix Grafted Sac7d-Cpep (A) Protein gel of soluble his6-tagged Sac7d and Sac7d-Cpep (B) 
ELISA data from E. coli cell lysate that encodes 5-Helix-His along with Sac7d, Sac7d-Cpep or C-peptide. 
Proteins were bound to a Ni-coated plate, washed, and incubated with an anti-FLAG antibody to measure 
binding. (C) Helix grafted Sac7d-C46 and Sac7d-Enfuviritide suppresses HIV-1 entry with similar potency 
to Sac7d-Cpep, C-peptide and Enfuviritide in a live virus assay. Error bars represent the standard error of 
the mean (SEM) for three separate experiments. If error bars are not visible, error is smaller than the data 
point. Data was plotted log[inhibitor], M. 
 
 
Figure S5.2: Generation 1 Screening and Analysis (A) flow cytometry data of generation 1 saturation 
mutagenesis protein library. Sort 1 contained 0.75 % of the yeast population displaying Sac7d-Cpep based 
library following incubation with FITC-labelled anti-myc antibody and 1 nM biotin-5-helix / streptavidin-
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phycoerythrin, and 10 nM of Cpep-ELMO competitor. Sort 2 contained 8.50 % of the amplified yeast 
population from the first sort displaying enriched Sac7d-Cpep library following incubation with FITC-
labelled anti-myc antibody and 100 pM biotin-5-helix / streptavidin-phycoerythrin, and 10 nM of Cpep-
ELMO competitor. (B) Affinity for 5-helix recognition was assessed by in vitro ELISA at 30 nM and 
lowest affinity binders were systematically removed from the pool of evolved proteins (less than 90 % of 
ELISA signal relative to Sac7d-Cpep). (C) Protein expression analysis relative to Sac7d-Cpep displays 






Figure S5.3: Generation 2 Screening and Analysis (A) flow cytometry data of generation 2 
saturation mutagenesis protein library. Sort 1 contained 3.00 % of the yeast population displaying 
Sac7d-Cpep based library following incubation with FITC-labelled anti-myc antibody and 4 nM 
biotin-5-helix / streptavidin-phycoerythrin without competitor. Sort 2 contained 2.50 % of the 
amplified yeast population from the first sort displaying enriched Sac7d-Cpep library following 
incubation with FITC-labelled anti-myc antibody and 200 pM biotin-5-helix / streptavidin-
phycoerythrin without competitor. Sort 3 contained 0.05 % of the amplified yeast population from 
the second sort displaying enriched Sac7d-Cpep library following incubation with FITC-labelled 
anti-myc antibody and 50 pM biotin-5-helix / streptavidin-phycoerythrin, and 1 nM of Sac7d-Cpep 
competitor. (B) Affinity for 5-helix recognition was assessed by in vitro ELISA at 30 nM and lowest 
affinity binders were systematically removed from the pool of evolved proteins (less than 100 % of 
ELISA signal relative to Sac7d-Cpep). (C) Protein expression analysis relative to Sac7d-Cpep 
displays improvement of expression in E. coli for the majority of remaining generation 2 evolved 





Figure S5.4: Polyclonal Potential for Enfuvirtide Resistance (A) Crystal structure of the NHR 
trimeric prefusogenic conformation with one hydrophobic groove occupied by a Cpeptide 
(PDB:1AIK). The labelled red spheres represent a common mutation found in Enfuvirtide-
resistant (Cpeptide sensitive) HIV-1 strains and its location relative to the variable regions of the 
evolved Sac7d-Cpep proteins. (B) Entry inhibition data for the second generation of evolved 
proteins was assessed by a live virus assay, and all the grafted proteins showed improvement in 
potency compared to Enfuvirtide (IC50 less than 60.0 +/- 11.6) and six of the grafted proteins 
showed improvement in potency compared to C-peptide (IC50 less than 23.2 +/- 4.1).  Data was 




Figure S5.5. Linker Optimization Infectivity (A) ELISA data from E. coli cell lysate that encodes 
either His-mCH3 or mFc in MCS2 along with FLAG Sac7d or FLAG Sac7d L33T (off) in MCS1. 
Proteins were bound to a Ni-coated plate, washed, and incubated with an anti-FLAG antibody to 
measure binding. (B) Infectivity mFc Sac7d-Cpep with and without a (GGS)3 linker. (C) Infectivity 
mCH3 Sac7d-Cpep with and without a (GGS)3 linker. (D) Infectivity of N- and C- terminal SAbp 
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fusions. The N terminal fusion does not contain a linker between the fusion peptide and Sac7d-
Cpep. The C terminal fusion contains a helix-forming linker in-between C-peptide and SAbp to 
help maintain structure. All infectivity data was plotted log[inhibitor], M. 
 











competitor, nM] Yeast Cells Screened Yeast Cells Sorted % double positive

























IC50 (nM) V38A IC50 (nM) V38A/N42D IC50 (nM)
1 Sac7d-Cpep W W E I Y T I L I S Q Q 1.9-12.4 +/- 0.2-1.3 4.1 +/- 0.6 5.4 +/- 0.4
2 Sac7d-C46 W W E I Y T I L I S Q Q 23.6 +/- 1.4 - -
3 Sac7d-Enfuvirtide Y T I L I S Q Q 39.7 +/- 1.2 - -
4 Cpeptide W W E I Y T I L I S Q Q 1.0-6.7 +/- 0.1-0.2 23.2 +/- 4.1 72.9 +/- 12.4
5 Enfuvirtide Y T I L I S Q Q 0.7-3.5 +/- 0.1-0.2 60.0 +/- 11.6 401.3 +/- 47.4
6 Sac7d-Cpep1.1 W W E A W L L L I S Q Q 2.6-6.2 +/- 0.3-0.6 3.7 +/- 0.4 2.1 +/- 0.2
7 Sac7d-Cpep1.2 W W E Y L I L L I S Q Q 7.7 +/- 1.4 - -
8 Sac7d-Cpep1.5 W W E I A L V L I S Q Q 5.4 +/- 0.9 - -
9 Sac7d-Cpep1.6 W W E T V M L L I S Q Q 7.0 +/- 1.2 - -
10 Sac7d-Cpep1.7 W W E L S W L L I S Q Q 9.4 +/- 1.4 - -
11 Sac7d-Cpep1.11 W W D V L L M L I S Q Q 5.8 +/- 1.0 - -
12 Sac7d-Cpep1.13 W W E L Y F S L I S Q Q 15.6 +/- 4.0 - -
13 Sac7d-Cpep2.5 W W E A W L L I V L T L 29.0 +/- 3.5 27.7 +/- 5.7 30.5 +/- 8.7
14 Sac7d-Cpep2.8 W W E A W L L L F L A Q 4.1 +/- 0.8 11.2 +/- 1.7 15.9 +/- 2.3
15 Sac7d-Cpep2.10 W W E A W L L L L M Q Q 5.1 +/- 1.5 7.7 +/- 1.8 4.3 +/- 0.6
16 Sac7d-Cpep2.13 W W E A W L L L I G M S 13.3 +/- 3.4 27.4 +/- 4.2 55.0 +/- 7.0
17 Sac7d-Cpep2.14 W W E A W L L I L I E I 20.7 +/- 7.9 44.8 +/- 8.5 83.7 +/- 16.7
18 Sac7d-Cpep2.19 W W E A W L L L L A R H 5.7 +/- 1.1 13.5 +/- 1.6 11.7 +/- 1.8
19 Sac7d-Cpep2.20 W W E A W L L F L A S Q 4.6 +/- 0.6 6.0 +/- 1.5 28.2 +/- 4.1
20 mFc-Sac7d-Cpep nl W W E I Y T I L I S Q Q 282.9 +/- 17.8 - -
21 mFc-GGS3-Sac7d-Cpep W W E I Y T I L I S Q Q 291.5 +/- 9.9 - -
22 mCH3-Sac7d-Cpep nl W W E I Y T I L I S Q Q 18.0 +/- 4.8 - -
23 mCH3-GGS3-Sac7d-Cpep W W E I Y T I L I S Q Q 9.8 +/- 3.8 - -
24 SAbp-Sac7d-Cpep nl W W E I Y T I L I S Q Q 3.9 +/- 0.8 - -
25 Sac7d-Cpep-hfl-SAbp W W E I Y T I L I S Q Q 9.7 +/- 1.1 - -
generation 1 generation 2
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AIDS    aquired immunodeficiency syndrome 
Ala/A    alanine  
Arg/R    arginine  
Asn/N    asparagine  
Asp/D    aspartic acid  
BSA   bovine serum albumin  
CD    circular dichroism  
Cfu    colony forming unit  
 Cys/C   cysteine  
Da    dalton  
DNA    deoxyribonucleic acid  
DTT    dithiothreitol  
ELISA   enzyme-linked immunosorbent assay  
ELMO   engulfment and cell motility 
FACS    fluorescence-activated cell sorting  
FDA    food and drug administration  
FITC    fluorescein isothiocyanate  
GFP    green fluorescent protein  
Gln/Q    glutamine  
Glu/E    glutamic acid  
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GLUE    gram like ubiquitin binding in EAP45 
Gly/G    glycine  
HA   hemagglutinin 
His/H    histidine  
HIV    human immunodeficiency virus  
HRP    horseradish peroxidase   
Ile/I    isoleucine  
IPTG    β-D-1-thiogalactopyranoside  
KD    dissociation Constant 
LC-MS  liquid chromatography mass spectrometry 
Leu/L    leucine 
Lys/K    lysine 
MCS    multiple cloning site 
Met/M   methionine 
NHR    N-heptad repeat 
NTA    nitrilotriacetic acid 
PAGE    polyacrylamide gel electrophoresis 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PDB    protein data bank 
PE    phycoerythrin  
PH Domain  pleckstrin homology domain 
	 107	
Phe/F    phenylalanine 
PPI    protein-protein interaction 
Pro/P    proline  
RT    room temperature  
RPM    revolutions per minute  
SAbp   serum albumin binding peptide 
SAPE    streptavidin-R-phycoerythrin  
SDS    sodium dodecyl sulfate  
SEM   standard of the mean 
Ser/S    serine  
sfGFP    superfolder green fluorescent protein  
spGFP   superpositive green fluorescent protein 
Thr/T    threonine  
TOF   time of flight 
TMB    3, 3ʹ, 5, 5ʹ-tetramethylbenzidine  
Tris   tris(hydroxymethyl) aminomethane 
Trp/W   tryptophan  
Tyr/Y    tyrosine  
Val/V    valine  
	
